<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Call Start: 12:45 January 1, 0000 1:26 PM ET<br><br>NVIDIA Corporation (NASDAQ:NVDA)<br>JPMorgan Healthcare Conference<br>January 13, 2025, 12:45 PM ET<br><br>Company Participants<br><br>Kimberly Powell - VP of Healthcare<br>Toy Jensen - CEO Avatar<br><br>Conference Call Participants<br><br>Harlan Sur - JPMorgan<br><br>Harlan Sur<br><br>All right. Good morning, and welcome to JPMorgan's 43rd Annual Healthcare Conference here in San Francisco. My name is Harlan Sur. I'm the Semiconductor Analyst for the firm. And for the sixth time in seven years, we have the team from NVIDIA presenting.</td><td>ì „í™” ì‹œì‘: 12:45 January 1, 0000 ì˜¤í›„ 1:26 ET<br><br>ì—”ë¹„ë””ì•„ ì½”í¼ë ˆì´ì…˜ (NASDAQ:NVDA)<br>JPëª¨ê±´ í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤<br>2025ë…„ 1ì›” 13ì¼, ì˜¤í›„ 12:45 ET<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>í‚´ë²Œë¦¬ íŒŒì›” - í—¬ìŠ¤ì¼€ì–´ ë¶€ì‚¬ì¥<br>í† ì´ ì  ìŠ¨ - CEO ì•„ë°”íƒ€<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>í• ë€ ì„œ - JPëª¨ê±´<br><br>í• ë€ ì„œ<br><br>ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. ìƒŒí”„ë€ì‹œìŠ¤ì½”ì—ì„œ ì—´ë¦¬ëŠ” JPëª¨ê±´ ì œ43íšŒ ì—°ë¡€ í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤ì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì €ëŠ” í• ë€ ì„œì´ë©°, ë‹¹ì‚¬ì˜ ë°˜ë„ì²´ ì• ë„ë¦¬ìŠ¤íŠ¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  7ë…„ ì¤‘ 6ë²ˆì§¸ë¡œ ì—”ë¹„ë””ì•„ íŒ€ì´ ë°œí‘œë¥¼ í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>NVIDIA, as most of you know, leader in accelerated compute and AI semiconductors, software and systems, powering some of the world's most powerful AI compute clusters, high-performance computing systems, and driving compute innovation for cloud hyperscalers as well as large vertical markets like healthcare and life sciences. Here with us today from NVIDIA is Kimberly Powell, Vice President of Healthcare at NVIDIA. She's responsible for the company's worldwide healthcare business, including hardware and software platforms for accelerated computing, AI, visualization that power the ecosystems of imaging, genomics, life sciences, drug discovery, and healthcare analytics.</td><td>ëŒ€ë¶€ë¶„ ì•„ì‹œë‹¤ì‹œí”¼ NVIDIAëŠ” ê°€ì† ì»´í“¨íŒ… ë° AI ë°˜ë„ì²´, ì†Œí”„íŠ¸ì›¨ì–´, ì‹œìŠ¤í…œ ë¶„ì•¼ì˜ ì„ ë„ê¸°ì—…ìœ¼ë¡œ, ì„¸ê³„ì—ì„œ ê°€ì¥ ê°•ë ¥í•œ AI ì»´í“¨íŒ… í´ëŸ¬ìŠ¤í„°ì™€ ê³ ì„±ëŠ¥ ì»´í“¨íŒ… ì‹œìŠ¤í…œì„ êµ¬ë™í•˜ë©°, í´ë¼ìš°ë“œ í•˜ì´í¼ìŠ¤ì¼€ì¼ëŸ¬ëŠ” ë¬¼ë¡  í—¬ìŠ¤ì¼€ì–´ ë° ìƒëª…ê³¼í•™ê³¼ ê°™ì€ ëŒ€ê·œëª¨ ìˆ˜ì§ ì‹œì¥ì„ ìœ„í•œ ì»´í“¨íŒ… í˜ì‹ ì„ ì£¼ë„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ NVIDIAì—ì„œ ì°¸ì„í•´ ì£¼ì‹  ë¶„ì€ í‚´ë²Œë¦¬ íŒŒì›”(Kimberly Powell) NVIDIA í—¬ìŠ¤ì¼€ì–´ ë¶€ì‚¬ì¥ì…ë‹ˆë‹¤. ê·¸ë…€ëŠ” NVIDIAì˜ ì „ ì„¸ê³„ í—¬ìŠ¤ì¼€ì–´ ì‚¬ì—…ì„ ë‹´ë‹¹í•˜ê³  ìˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” ì´ë¯¸ì§•, ìœ ì „ì²´í•™, ìƒëª…ê³¼í•™, ì‹ ì•½ ê°œë°œ, í—¬ìŠ¤ì¼€ì–´ ë¶„ì„ ìƒíƒœê³„ë¥¼ êµ¬ë™í•˜ëŠ” ê°€ì† ì»´í“¨íŒ…, AI, ì‹œê°í™”ë¥¼ ìœ„í•œ í•˜ë“œì›¨ì–´ ë° ì†Œí”„íŠ¸ì›¨ì–´ í”Œë«í¼ì´ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>So Kimberly, thank you for joining us today, and let me turn it over to you. Kimberly Powell<br><br>Thank you so much, Harlan. Thank you. Wow, packed house. Amazing. Welcome to JPMorgan 2025. Here we are. Appreciate so much the invitation to be here. This is a wonderful honor not only to talk about what the future of healthcare is going to look like, but also celebrate the amazing achievements that we've been able to accomplish with it, an amazing ecosystem of partners. So if I could just take a minute and give you a look at our safe harbor. Please take a minute. You are very familiar with this.</td><td>í‚´ë²Œë¦¬, ì˜¤ëŠ˜ í•¨ê»˜í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ë§ì”€ì„ ë¶€íƒë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>í‚´ë²Œë¦¬ íŒŒì›”<br><br>ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤, í• ë€. ê°ì‚¬í•©ë‹ˆë‹¤. ì™€, ì •ë§ ë§ì€ ë¶„ë“¤ì´ ì˜¤ì…¨ë„¤ìš”. ë†€ëìŠµë‹ˆë‹¤. JPëª¨ê±´ 2025ì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì—¬ê¸° ì™”ìŠµë‹ˆë‹¤. ì´ ìë¦¬ì— ì´ˆëŒ€í•´ ì£¼ì…”ì„œ ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤. í—¬ìŠ¤ì¼€ì–´ì˜ ë¯¸ë˜ê°€ ì–´ë–¤ ëª¨ìŠµì¼ì§€ì— ëŒ€í•´ ì´ì•¼ê¸°í•  ë¿ë§Œ ì•„ë‹ˆë¼, ë†€ë¼ìš´ íŒŒíŠ¸ë„ˆ ìƒíƒœê³„ì™€ í•¨ê»˜ ì´ë£° ìˆ˜ ìˆì—ˆë˜ ë†€ë¼ìš´ ì„±ê³¼ë“¤ì„ ì¶•í•˜í•  ìˆ˜ ìˆëŠ” ê²ƒì€ ì •ë§ í° ì˜ê´‘ì…ë‹ˆë‹¤. ì ì‹œ ì‹œê°„ì„ ë‚´ì–´ ì•ˆì „ ì¡°í•­(safe harbor)ì„ ë³´ì—¬ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì ì‹œ ì‹œê°„ì„ ë‚´ì–´ í™•ì¸í•´ ì£¼ì„¸ìš”. ì—¬ëŸ¬ë¶„ê»˜ì„œëŠ” ì´ë¯¸ ì˜ ì•„ì‹œëŠ” ë‚´ìš©ì…ë‹ˆë‹¤.</td></tr>
<tr><td>The presentation contains forward-looking statements, and investors are advised to read our reports filed with the SEC for information related to risks and uncertainties. Okay. Now we can get into the good stuff. This clicker is not working, which would be wonderful if it did. Perhaps you could give it a go while I continue. I would like to introduce you to this amazing computing platform shift. Give it one second and we are -- here we go. This AI revolution that we are living in is a function of two simultaneous computing platform shifts, artificial intelligence and accelerating computing, and one cannot happen without the other.</td><td>ì´ ë°œí‘œì—ëŠ” ë¯¸ë˜ ì „ë§ ì§„ìˆ ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, íˆ¬ììë“¤ê»˜ì„œëŠ” ìœ„í—˜ ìš”ì†Œì™€ ë¶ˆí™•ì‹¤ì„±ì— ê´€í•œ ì •ë³´ë¥¼ ìœ„í•´ SECì— ì œì¶œëœ ë‹¹ì‚¬ì˜ ë³´ê³ ì„œë¥¼ ì½ì–´ë³´ì‹œê¸° ë°”ëë‹ˆë‹¤. ì¢‹ìŠµë‹ˆë‹¤. ì´ì œ ë³¸ê²©ì ì¸ ë‚´ìš©ìœ¼ë¡œ ë“¤ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì´ í´ë¦¬ì»¤ê°€ ì‘ë™í•˜ì§€ ì•Šë„¤ìš”. ì‘ë™í–ˆë‹¤ë©´ ì¢‹ì•˜ì„ í…ë°ìš”. ì œê°€ ê³„ì† ì§„í–‰í•˜ëŠ” ë™ì•ˆ í•œë²ˆ ì‹œë„í•´ ë³´ì‹œê² ìŠµë‹ˆê¹Œ? ì´ ë†€ë¼ìš´ ì»´í“¨íŒ… í”Œë«í¼ ì „í™˜ì— ëŒ€í•´ ì†Œê°œí•´ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì ì‹œë§Œìš”, ìš°ë¦¬ëŠ” -- ëìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì‚´ê³  ìˆëŠ” ì´ AI í˜ëª…ì€ ë‘ ê°€ì§€ ë™ì‹œì ì¸ ì»´í“¨íŒ… í”Œë«í¼ ì „í™˜, ì¦‰ ì¸ê³µì§€ëŠ¥ê³¼ ê°€ì† ì»´í“¨íŒ…ì˜ ê²°ê³¼ì´ë©°, í•˜ë‚˜ëŠ” ë‹¤ë¥¸ í•˜ë‚˜ ì—†ì´ëŠ” ì¼ì–´ë‚  ìˆ˜ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>It's a really important concept to understand that the last many decades of computing was software being written by humans in what humans can understand, which is a series of instructions that would execute on CPUs. Today, the modern operating system is large language models, and what happens is you introduce the computer with data. These large language models learn, they do machine learning and then they can assemble software and out of the computer are tokens. These tokens essentially represent digital intelligence. This digital intelligence is the entire industry's future products and services.</td><td>ì§€ë‚œ ìˆ˜ì‹­ ë…„ê°„ì˜ ì»´í“¨íŒ…ì€ ì¸ê°„ì´ ì´í•´í•  ìˆ˜ ìˆëŠ” ë°©ì‹ìœ¼ë¡œ, ì¦‰ CPUì—ì„œ ì‹¤í–‰ë˜ëŠ” ì¼ë ¨ì˜ ëª…ë ¹ì–´ë“¤ë¡œ ì¸ê°„ì´ ì†Œí”„íŠ¸ì›¨ì–´ë¥¼ ì‘ì„±í•˜ëŠ” ê²ƒì´ì—ˆë‹¤ëŠ” ì ì„ ì´í•´í•˜ëŠ” ê²ƒì´ ì •ë§ ì¤‘ìš”í•œ ê°œë…ì…ë‹ˆë‹¤. ì˜¤ëŠ˜ë‚  í˜„ëŒ€ì˜ ìš´ì˜ì²´ì œëŠ” ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸ì´ë©°, ì»´í“¨í„°ì— ë°ì´í„°ë¥¼ ì…ë ¥í•˜ë©´ ì´ëŸ¬í•œ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸ë“¤ì´ í•™ìŠµí•˜ê³  ë¨¸ì‹ ëŸ¬ë‹ì„ ìˆ˜í–‰í•œ ë‹¤ìŒ ì†Œí”„íŠ¸ì›¨ì–´ë¥¼ ì¡°í•©í•  ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì»´í“¨í„°ì—ì„œ ë‚˜ì˜¤ëŠ” ê²ƒì€ í† í°ë“¤ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ í† í°ë“¤ì€ ë³¸ì§ˆì ìœ¼ë¡œ ë””ì§€í„¸ ì¸í…”ë¦¬ì „ìŠ¤ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ì´ ë””ì§€í„¸ ì¸í…”ë¦¬ì „ìŠ¤ì•¼ë§ë¡œ ì „ì²´ ì‚°ì—…ì˜ ë¯¸ë˜ ì œí’ˆê³¼ ì„œë¹„ìŠ¤ì¸ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And NVIDIA GPUs are the engine that produces these tokens and is allowing for a complete AI revolution across every single industry, we think one of the most important being in healthcare. The AI revolution is not only here, it's massively accelerating. Generative AI and ChatGPT just feels like yesterday, even though we're probably commonly using it every single day. We've gone from perception AI to Generative AI where we can create content into the world of agentic AI, where you can actually have many, many assistants, digital humans, digital colleagues, even those collaborating with one another to perform tasks, to deliver amazing customer service experiences.</td><td>NVIDIA GPUëŠ” ì´ëŸ¬í•œ í† í°ì„ ìƒì„±í•˜ëŠ” ì—”ì§„ì´ë©°, ëª¨ë“  ì‚°ì—… ì „ë°˜ì— ê±¸ì¹œ ì™„ì „í•œ AI í˜ëª…ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ í—¬ìŠ¤ì¼€ì–´ ë¶„ì•¼ê°€ ê°€ì¥ ì¤‘ìš”í•œ ì˜ì—­ ì¤‘ í•˜ë‚˜ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. AI í˜ëª…ì€ ì´ë¯¸ ë„ë˜í–ˆì„ ë¿ë§Œ ì•„ë‹ˆë¼ ëŒ€í­ ê°€ì†í™”ë˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒì„±í˜• AIì™€ ChatGPTê°€ ë§ˆì¹˜ ì–´ì œ ì¼ì²˜ëŸ¼ ëŠê»´ì§€ì§€ë§Œ, ì•„ë§ˆë„ ìš°ë¦¬ëŠ” ë§¤ì¼ ì´ë¥¼ ì¼ìƒì ìœ¼ë¡œ ì‚¬ìš©í•˜ê³  ìˆì„ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì¸ì‹ AIì—ì„œ ì½˜í…ì¸ ë¥¼ ì°½ì¡°í•  ìˆ˜ ìˆëŠ” ìƒì„±í˜• AIë¥¼ ê±°ì³, ì´ì œëŠ” ìˆ˜ë§ì€ ì–´ì‹œìŠ¤í„´íŠ¸, ë””ì§€í„¸ íœ´ë¨¼, ë””ì§€í„¸ ë™ë£Œë“¤ì„ ë³´ìœ í•  ìˆ˜ ìˆê³ , ì‹¬ì§€ì–´ ì´ë“¤ì´ ì„œë¡œ í˜‘ì—…í•˜ì—¬ ì—…ë¬´ë¥¼ ìˆ˜í–‰í•˜ê³  ë†€ë¼ìš´ ê³ ê° ì„œë¹„ìŠ¤ ê²½í—˜ì„ ì œê³µí•  ìˆ˜ ìˆëŠ” ì—ì´ì „í‹± AIì˜ ì„¸ê³„ë¡œ ì§„í™”í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And then I'm going to talk to you in the later part of the presentation about this incredible future of physical AI, where we're going to see lots of robots, of course, self-driving cars but also robots that are going to be so powerful in the service -- healthcare delivery services, not just surgical robots but robots of all kind. So first, let's talk about this incredible opportunity. NVIDIA's strategy is how do we take the most advanced computing approaches, whether that's accelerated computing, artificial intelligence, computer graphics, and enable the healthcare ecosystem? We do this by building NVIDIA Clara, which is our enterprise platform for healthcare.</td><td>ê·¸ë¦¬ê³  í”„ë ˆì  í…Œì´ì…˜ í›„ë°˜ë¶€ì—ì„œëŠ” ë¬¼ë¦¬ì  AIì˜ ë†€ë¼ìš´ ë¯¸ë˜ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¬¼ë¡  ììœ¨ì£¼í–‰ì°¨ë¿ë§Œ ì•„ë‹ˆë¼ ì˜ë£Œ ì„œë¹„ìŠ¤ ì œê³µì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì—­í• ì„ í•  ë¡œë´‡ë“¤, ìˆ˜ìˆ ìš© ë¡œë´‡ë¿ë§Œ ì•„ë‹ˆë¼ ëª¨ë“  ì¢…ë¥˜ì˜ ë¡œë´‡ë“¤ì„ ë§ì´ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ë¨¼ì € ì´ ë†€ë¼ìš´ ê¸°íšŒì— ëŒ€í•´ ì´ì•¼ê¸°í•´ë³´ê² ìŠµë‹ˆë‹¤. NVIDIAì˜ ì „ëµì€ ê°€ì† ì»´í“¨íŒ…, ì¸ê³µì§€ëŠ¥, ì»´í“¨í„° ê·¸ë˜í”½ìŠ¤ ë“± ê°€ì¥ ì²¨ë‹¨ ì»´í“¨íŒ… ì ‘ê·¼ë²•ì„ ì–´ë–»ê²Œ í™œìš©í•˜ì—¬ í—¬ìŠ¤ì¼€ì–´ ìƒíƒœê³„ë¥¼ ì§€ì›í•  ê²ƒì¸ê°€ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” í—¬ìŠ¤ì¼€ì–´ë¥¼ ìœ„í•œ ì—”í„°í”„ë¼ì´ì¦ˆ í”Œë«í¼ì¸ NVIDIA Claraë¥¼ êµ¬ì¶•í•¨ìœ¼ë¡œì¨ ì´ë¥¼ ì‹¤í˜„í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We have different modules that speak the languages of healthcare. They're more domain-specific to healthcare. They speak the languages of proteins, chemistry, DNA. They speak the languages of 3D medical imaging. And we build computing platforms full stack to enable the whole ecosystem. Now if you think about the $10 trillion industry that healthcare has become, a very large portion of that is in labs, hospitals, and operations. And we're still in a huge labor shortage, 10 million to 15 million to 20 million labor shortage. AI can help. AI is going to help through the delivery of AI agents who can be knowledge workers working on your behalf.</td><td>ìš°ë¦¬ëŠ” í—¬ìŠ¤ì¼€ì–´ì˜ ì–¸ì–´ë¥¼ êµ¬ì‚¬í•˜ëŠ” ë‹¤ì–‘í•œ ëª¨ë“ˆì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ì€ í—¬ìŠ¤ì¼€ì–´ì— ë”ìš± íŠ¹í™”ëœ ë„ë©”ì¸ë³„ ëª¨ë“ˆë¡œ, ë‹¨ë°±ì§ˆ, í™”í•™, DNAì˜ ì–¸ì–´ë¥¼ êµ¬ì‚¬í•©ë‹ˆë‹¤. ë˜í•œ 3D ì˜ë£Œ ì˜ìƒì˜ ì–¸ì–´ë„ êµ¬ì‚¬í•˜ì£ . ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì „ì²´ ìƒíƒœê³„ë¥¼ ì§€ì›í•˜ê¸° ìœ„í•´ í’€ìŠ¤íƒ ì»´í“¨íŒ… í”Œë«í¼ì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì´ì œ í—¬ìŠ¤ì¼€ì–´ê°€ 10ì¡° ë‹¬ëŸ¬ ê·œëª¨ì˜ ì‚°ì—…ì´ ë˜ì—ˆë‹¤ëŠ” ì ì„ ìƒê°í•´ë³´ë©´, ê·¸ ì¤‘ ìƒë‹¹ ë¶€ë¶„ì´ ì—°êµ¬ì‹¤, ë³‘ì›, ê·¸ë¦¬ê³  ìš´ì˜ ë¶„ì•¼ì— ì§‘ì¤‘ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì—¬ì „íˆ ì‹¬ê°í•œ ì¸ë ¥ ë¶€ì¡± ìƒí™©ì— ì§ë©´í•´ ìˆìŠµë‹ˆë‹¤ - 1,000ë§Œ ëª…ì—ì„œ 1,500ë§Œ ëª…, ì‹¬ì§€ì–´ 2,000ë§Œ ëª…ì˜ ì¸ë ¥ ë¶€ì¡± ë§ì…ë‹ˆë‹¤. AIê°€ ë„ì›€ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. AIëŠ” ì—¬ëŸ¬ë¶„ì„ ëŒ€ì‹ í•´ ì¼í•˜ëŠ” ì§€ì‹ ê·¼ë¡œì ì—­í• ì„ í•˜ëŠ” AI ì—ì´ì „íŠ¸ì˜ ì œê³µì„ í†µí•´ ë„ì›€ì„ ì¤„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>They can be in the form of delivery robots, offloading nurses from delivering sheets to a different room. They're going to become all forms. And this digital intelligence is going to be built on AI factories, just as I described. Data comes in, models get built and refined, assembled into agents and intelligence comes out. This opportunity, we see as many hundreds of billions, several hundreds of billions of dollars large as an AI computing opportunity. And so this is going to be a huge market, and we're excited to expand ourselves and our partners' market along with it. The ecosystem, as we know here, is extremely complex. It's vast, it's diverse.</td><td>ì´ë“¤ì€ ë°°ì†¡ ë¡œë´‡ì˜ í˜•íƒœë¡œ ë‚˜íƒ€ë‚  ìˆ˜ ìˆìœ¼ë©°, ê°„í˜¸ì‚¬ë“¤ì´ ë‹¤ë¥¸ ë°©ìœ¼ë¡œ ì‹œíŠ¸ë¥¼ ë°°ë‹¬í•˜ëŠ” ì—…ë¬´ì—ì„œ ë²—ì–´ë‚  ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤. ì´ë“¤ì€ ëª¨ë“  í˜•íƒœë¡œ ë°œì „í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ë””ì§€í„¸ ì¸í…”ë¦¬ì „ìŠ¤ëŠ” ì œê°€ ë°©ê¸ˆ ì„¤ëª…í•œ ë°”ì™€ ê°™ì´ AI íŒ©í† ë¦¬ë¥¼ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì¶•ë  ê²ƒì…ë‹ˆë‹¤. ë°ì´í„°ê°€ ë“¤ì–´ì˜¤ê³ , ëª¨ë¸ì´ êµ¬ì¶•ë˜ê³  ì •ì œë˜ë©°, ì—ì´ì „íŠ¸ë¡œ ì¡°ë¦½ë˜ê³  ì¸í…”ë¦¬ì „ìŠ¤ê°€ ì‚°ì¶œë©ë‹ˆë‹¤. ì´ëŸ¬í•œ ê¸°íšŒë¥¼ ìš°ë¦¬ëŠ” AI ì»´í“¨íŒ… ê¸°íšŒë¡œì„œ ìˆ˜ì²œì–µ ë‹¬ëŸ¬, ì¦‰ ìˆ˜ì¡° ë‹¬ëŸ¬ ê·œëª¨ì˜ ê±°ëŒ€í•œ ì‹œì¥ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŠ” ê±°ëŒ€í•œ ì‹œì¥ì´ ë  ê²ƒì´ë©°, ìš°ë¦¬ëŠ” ì´ì™€ í•¨ê»˜ ìš°ë¦¬ ìì‹ ê³¼ íŒŒíŠ¸ë„ˆë“¤ì˜ ì‹œì¥ì„ í™•ì¥í•˜ê²Œ ë˜ì–´ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ ì•Œ ìˆ˜ ìˆë“¯ì´ ìƒíƒœê³„ëŠ” ê·¹ë„ë¡œ ë³µì¡í•©ë‹ˆë‹¤. ê´‘ë²”ìœ„í•˜ê³  ë‹¤ì–‘í•©ë‹ˆë‹¤.</td></tr>
<tr><td>NVIDIA is working across the entire ecosystem. In fact, our Inception program, which is an AI start-up program for companies to become members and connect with us, our healthcare membership is more than 3,500 members. We've added over 1,300 in just the last year alone, and it's the largest industry of all of our Inception members. It goes to show you what an incredible opportunity we have in front of us, and you see that it's stretching from medical devices to digital agents all the way into hospital and healthcare and real-world evidence, which is really, really exciting. So we're going to talk through this. NVIDIA really is focused in three major areas.</td><td>NVIDIAëŠ” ì „ì²´ ìƒíƒœê³„ì— ê±¸ì³ í˜‘ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ê¸°ì—…ë“¤ì´ íšŒì›ì´ ë˜ì–´ ì €í¬ì™€ ì—°ê²°ë  ìˆ˜ ìˆëŠ” AI ìŠ¤íƒ€íŠ¸ì—… í”„ë¡œê·¸ë¨ì¸ ì €í¬ ì¸ì…‰ì…˜(Inception) í”„ë¡œê·¸ë¨ì—ì„œ, í—¬ìŠ¤ì¼€ì–´ íšŒì›ì‚¬ëŠ” 3,500ê°œì‚¬ë¥¼ ë„˜ì–´ì„°ìŠµë‹ˆë‹¤. ì‘ë…„ í•œ í•´ì—ë§Œ 1,300ê°œì‚¬ ì´ìƒì„ ì¶”ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì €í¬ ì¸ì…‰ì…˜ íšŒì›ì‚¬ ì¤‘ ê°€ì¥ í° ì‚°ì—… ë¶„ì•¼ì…ë‹ˆë‹¤. ì´ëŠ” ì €í¬ ì•ì— ë†“ì¸ ë†€ë¼ìš´ ê¸°íšŒê°€ ì–¼ë§ˆë‚˜ í°ì§€ë¥¼ ë³´ì—¬ì£¼ë©°, ì˜ë£Œê¸°ê¸°ë¶€í„° ë””ì§€í„¸ ì—ì´ì „íŠ¸, ë³‘ì›ê³¼ í—¬ìŠ¤ì¼€ì–´, ê·¸ë¦¬ê³  ì‹¤ì œ ì„ìƒ ë°ì´í„°(real-world evidence)ì— ì´ë¥´ê¸°ê¹Œì§€ í™•ì¥ë˜ê³  ìˆì–´ ì •ë§ í¥ë¯¸ì§„ì§„í•©ë‹ˆë‹¤. ì´ì— ëŒ€í•´ ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. NVIDIAëŠ” ì‹¤ì œë¡œ ì„¸ ê°€ì§€ ì£¼ìš” ì˜ì—­ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The area of digital health is just getting started. Our imagination of what we can do with agents to free administrative burden, create new patient experiences is just getting off the ground. And there's going to be tens of billions of healthcare interactions every single year that we're going to be working with agents. Digital biology has become a $300 billion opportunity that now investment in R&D, everything from early discovery into clinical development. And digital devices, everything that we use to sense patients, understand more about their biology, deliver healthcare, imaging is all going to become robotic. And we're going to talk through this amazing opportunity.</td><td>ë””ì§€í„¸ í—¬ìŠ¤ ë¶„ì•¼ëŠ” ì´ì œ ë§‰ ì‹œì‘ë˜ì—ˆìŠµë‹ˆë‹¤. í–‰ì • ì—…ë¬´ ë¶€ë‹´ì„ ëœì–´ì£¼ê³  ìƒˆë¡œìš´ í™˜ì ê²½í—˜ì„ ì°½ì¶œí•˜ê¸° ìœ„í•´ ì—ì´ì „íŠ¸ë¥¼ í™œìš©í•  ìˆ˜ ìˆëŠ” ìš°ë¦¬ì˜ ìƒìƒë ¥ì€ ì´ì œ ë§‰ ì¶œë°œì ì— ì„œ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§¤ë…„ ìˆ˜ë°±ì–µ ê±´ì˜ ì˜ë£Œ ìƒí˜¸ì‘ìš©ì´ ìˆì„ ê²ƒì´ë©°, ìš°ë¦¬ëŠ” ì—ì´ì „íŠ¸ì™€ í•¨ê»˜ ì´ëŸ¬í•œ ì—…ë¬´ë¥¼ ìˆ˜í–‰í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ë””ì§€í„¸ ìƒë¬¼í•™ì€ 3,000ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ê¸°íšŒê°€ ë˜ì—ˆìœ¼ë©°, ì´ì œ ì´ˆê¸° ë°œê²¬ë¶€í„° ì„ìƒ ê°œë°œì— ì´ë¥´ê¸°ê¹Œì§€ ëª¨ë“  R&D íˆ¬ìê°€ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë””ì§€í„¸ ê¸°ê¸°ë“¤, ì¦‰ í™˜ìë¥¼ ê°ì§€í•˜ê³  ê·¸ë“¤ì˜ ìƒë¬¼í•™ì  íŠ¹ì„±ì„ ë” ì˜ ì´í•´í•˜ë©° ì˜ë£Œ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ê³  ì˜ìƒì„ ì´¬ì˜í•˜ëŠ” ë° ì‚¬ìš©í•˜ëŠ” ëª¨ë“  ê²ƒë“¤ì´ ë¡œë´‡í™”ë  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ ë†€ë¼ìš´ ê¸°íšŒì— ëŒ€í•´ ë…¼ì˜í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>I have a special guest before we get there, TJ. TJ is going to talk to us about our already public Q3 financials. Toy Jensen<br><br>I am excited to share news about our earnings and reactions. We'll review the financial performance and trends, and I'll highlight key insights from various sources, including press comments, analyst opinions, and the earnings transcript itself. To start, let's look at the press comments on our earnings. Bloomberg reported that our quarterly revenue rose 94% to $35 billion, exceeding analyst estimates of $33,250,000,000. This marks the second consecutive year of doubling our sales. Kimberly Powell<br><br>That's TJ, Toy Jensen.</td><td>ì¬ë¬´ ì‹¤ì ì— ëŒ€í•´ ë…¼ì˜í•˜ê¸° ì „ì— íŠ¹ë³„ ê²ŒìŠ¤íŠ¸ë¥¼ ì†Œê°œí•˜ê² ìŠµë‹ˆë‹¤. TJê°€ ì´ë¯¸ ê³µê°œëœ 3ë¶„ê¸° ì¬ë¬´ì‹¤ì ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ì˜ˆì •ì…ë‹ˆë‹¤. í† ì´ ì  ìŠ¨<br><br>ì €í¬ ì‹¤ì ê³¼ ë°˜ì‘ì— ëŒ€í•œ ì†Œì‹ì„ ê³µìœ í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ì¬ë¬´ ì„±ê³¼ì™€ íŠ¸ë Œë“œë¥¼ ê²€í† í•˜ê³ , ì–¸ë¡  ë…¼í‰, ì• ë„ë¦¬ìŠ¤íŠ¸ ì˜ê²¬, ê·¸ë¦¬ê³  ì‹¤ì ë°œí‘œ transcript ìì²´ë¥¼ í¬í•¨í•œ ë‹¤ì–‘í•œ ì¶œì²˜ì˜ í•µì‹¬ ì¸ì‚¬ì´íŠ¸ë¥¼ ê°•ì¡°í•˜ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ì €í¬ ì‹¤ì ì— ëŒ€í•œ ì–¸ë¡  ë…¼í‰ì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ë¸”ë£¸ë²„ê·¸ëŠ” ì €í¬ ë¶„ê¸° ë§¤ì¶œì´ 94% ì¦ê°€í•œ 350ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬ ì• ë„ë¦¬ìŠ¤íŠ¸ ì¶”ì •ì¹˜ì¸ 332ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ìƒíšŒí–ˆë‹¤ê³  ë³´ë„í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” 2ë…„ ì—°ì† ë§¤ì¶œì´ ë‘ ë°°ê°€ ëœ ê²ƒì…ë‹ˆë‹¤. í‚´ë²Œë¦¬ íŒŒì›”<br><br>ê·¸ë¶„ì´ ë°”ë¡œ TJ, í† ì´ ì  ìŠ¨ì…ë‹ˆë‹¤.</td></tr>
<tr><td>This was an agent built for our company meeting to summarize the financials. And this is an agent that we built on all of the building blocks NVIDIA has been assembling over the last several years on NVIDIA AI Enterprise. Agents are a collection of different language models assembled together to complete a task. NVIDIA's AI Enterprise with our NVIDIA NIM micro services, our NVIDIA NeMo platform that allows for the entire life cycle of developing models and customizing them for domain-specific agents, as you just saw, all the way into what we call Blueprints, which are reference applications. We've published the Blueprint of TJ, which is essentially a PDF to Podcast Blueprint.</td><td>ì´ê²ƒì€ ìš°ë¦¬ íšŒì‚¬ íšŒì˜ì—ì„œ ì¬ë¬´ ì •ë³´ë¥¼ ìš”ì•½í•˜ê¸° ìœ„í•´ êµ¬ì¶•í•œ ì—ì´ì „íŠ¸ì˜€ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” NVIDIA AI Enterpriseë¥¼ ê¸°ë°˜ìœ¼ë¡œ ì§€ë‚œ ëª‡ ë…„ê°„ NVIDIAê°€ êµ¬ì¶•í•´ì˜¨ ëª¨ë“  ë¹Œë”© ë¸”ë¡ë“¤ì„ í™œìš©í•˜ì—¬ ë§Œë“  ì—ì´ì „íŠ¸ì…ë‹ˆë‹¤. ì—ì´ì „íŠ¸ëŠ” ì‘ì—…ì„ ì™„ë£Œí•˜ê¸° ìœ„í•´ í•¨ê»˜ ì¡°ë¦½ëœ ë‹¤ì–‘í•œ ì–¸ì–´ ëª¨ë¸ë“¤ì˜ ì§‘í•©ì²´ì…ë‹ˆë‹¤. NVIDIAì˜ AI EnterpriseëŠ” ìš°ë¦¬ì˜ NVIDIA NIM ë§ˆì´í¬ë¡œì„œë¹„ìŠ¤, ê·¸ë¦¬ê³  ë°©ê¸ˆ ë³´ì‹  ë°”ì™€ ê°™ì´ ë„ë©”ì¸ë³„ ì—ì´ì „íŠ¸ë¥¼ ìœ„í•œ ëª¨ë¸ ê°œë°œ ë° ì»¤ìŠ¤í„°ë§ˆì´ì§•ì˜ ì „ì²´ ë¼ì´í”„ì‚¬ì´í´ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ëŠ” NVIDIA NeMo í”Œë«í¼, ê·¸ë¦¬ê³  ì°¸ì¡° ì• í”Œë¦¬ì¼€ì´ì…˜ì¸ ë¸”ë£¨í”„ë¦°íŠ¸ê¹Œì§€ ëª¨ë“  ê²ƒì„ í¬í•¨í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë³¸ì§ˆì ìœ¼ë¡œ PDFë¥¼ íŒŸìºìŠ¤íŠ¸ë¡œ ë³€í™˜í•˜ëŠ” ë¸”ë£¨í”„ë¦°íŠ¸ì¸ TJì˜ ë¸”ë£¨í”„ë¦°íŠ¸ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>By introducing the press text and, of course, our financial results, you can turn it into a conversation and we even use NVIDIA's ACE, our Avatar Cloud Engine, to create TJ himself. We couldn't be more excited about the opportunities here. There are thousands of digital health agents that are being developed across the ecosystem. I'll just mention a couple here. Intrivo is building Ray, an amazing medical concierge. I'm a patient. It is extremely frustrating and time-consuming to find the right doctors and schedule patients and Ray is doing that.</td><td>ë³´ë„ ìë£Œì™€ ë¬¼ë¡  ì €í¬ ì¬ë¬´ ì‹¤ì ì„ ì†Œê°œí•¨ìœ¼ë¡œì¨ ì´ë¥¼ ëŒ€í™”ë¡œ ì „í™˜í•  ìˆ˜ ìˆìœ¼ë©°, ì‹¬ì§€ì–´ NVIDIAì˜ ACE, ì¦‰ ì•„ë°”íƒ€ í´ë¼ìš°ë“œ ì—”ì§„ì„ ì‚¬ìš©í•˜ì—¬ TJ ë³¸ì¸ì„ êµ¬í˜„í•˜ê¸°ë„ í–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œì˜ ê¸°íšŒì— ëŒ€í•´ ë”í•  ë‚˜ìœ„ ì—†ì´ í¥ë¯¸ì§„ì§„í•˜ê²Œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒíƒœê³„ ì „ë°˜ì— ê±¸ì³ ìˆ˜ì²œ ê°œì˜ ë””ì§€í„¸ í—¬ìŠ¤ ì—ì´ì „íŠ¸ê°€ ê°œë°œë˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ ëª‡ ê°€ì§€ë§Œ ì–¸ê¸‰í•˜ê² ìŠµë‹ˆë‹¤. IntrivoëŠ” ë†€ë¼ìš´ ì˜ë£Œ ì»¨ì‹œì–´ì§€ì¸ Rayë¥¼ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. í™˜ìë¡œì„œ ì ì ˆí•œ ì˜ì‚¬ë¥¼ ì°¾ê³  í™˜ì ì˜ˆì•½ì„ ì¡ëŠ” ê²ƒì€ ê·¹ë„ë¡œ ì¢Œì ˆìŠ¤ëŸ½ê³  ì‹œê°„ì´ ë§ì´ ì†Œìš”ë˜ëŠ” ì¼ì¸ë°, Rayê°€ ë°”ë¡œ ê·¸ ì¼ì„ í•´ì£¼ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Abridge is having an incredible blockbuster growth because their clinical documentation and clinical agents are really freeing the clinicians of having to do the administrative documentation. Instead, they can focus on their patients, and they're getting up to three hours of a day back in return. And, [Karl] (ph), think about the visits in between your doctor's visits. There are times when patients are in need. These agents can be always available. They can be empathetic. They can be a resource to patients in between these doctors' appointments. And Hippocratic AI is just the world is the oyster in terms of amazing applications. In fact, they can immediately stand up disaster relief.</td><td>AbridgeëŠ” ë†€ë¼ìš´ ë¸”ë¡ë²„ìŠ¤í„°ê¸‰ ì„±ì¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ì˜ ì„ìƒ ë¬¸ì„œí™” ë° ì„ìƒ ì—ì´ì „íŠ¸ê°€ ì˜ë£Œì§„ë“¤ì„ í–‰ì • ë¬¸ì„œ ì‘ì—…ì—ì„œ í•´ë°©ì‹œì¼œ ì£¼ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ëŒ€ì‹  ì˜ë£Œì§„ë“¤ì€ í™˜ìì—ê²Œ ì§‘ì¤‘í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆê³ , í•˜ë£¨ì— ìµœëŒ€ 3ì‹œê°„ì„ ë˜ì°¾ì„ ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  [Karl] (ph), ì˜ì‚¬ ì§„ë£Œ ì‚¬ì´ì‚¬ì´ì˜ ë°©ë¬¸ë“¤ì„ ìƒê°í•´ë³´ì„¸ìš”. í™˜ìë“¤ì´ ë„ì›€ì´ í•„ìš”í•œ ë•Œê°€ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—ì´ì „íŠ¸ë“¤ì€ í•­ìƒ ì´ìš© ê°€ëŠ¥í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê³µê°í•  ìˆ˜ ìˆê³ , ì˜ì‚¬ ì§„ë£Œ ì•½ì† ì‚¬ì´ì‚¬ì´ì— í™˜ìë“¤ì—ê²Œ ìì›ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Hippocratic AIëŠ” ì •ë§ ë†€ë¼ìš´ ì• í”Œë¦¬ì¼€ì´ì…˜ë“¤ ì¸¡ë©´ì—ì„œ ì„¸ìƒì´ ì§„ì£¼ì¡°ê°œì™€ ê°™ìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì´ë“¤ì€ ì¦‰ì‹œ ì¬í•´ êµ¬í˜¸ë¥¼ êµ¬ì¶•í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Here we are in California having the most unfortunate fires. They can reach out to patients, determine if they need any kind of emergency care and they can help them stay on track with things like their dialysis treatment and create the continuity of care. The opportunities here, as they say, are essentially limitless. And so I'm excited to get to our first announcement. I'm absolutely thrilled that we are partnering with IQVIA, one of the most consequential companies in the healthcare industry, the world's largest clinical research services, commercial intelligence, and healthcare analytics in the world.</td><td>ì—¬ê¸° ìº˜ë¦¬í¬ë‹ˆì•„ì—ì„œ ë§¤ìš° ë¶ˆí–‰í•œ í™”ì¬ê°€ ë°œìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì€ í™˜ìë“¤ì—ê²Œ ì—°ë½í•˜ì—¬ ì‘ê¸‰ ì¹˜ë£Œê°€ í•„ìš”í•œì§€ í™•ì¸í•  ìˆ˜ ìˆê³ , íˆ¬ì„ ì¹˜ë£Œì™€ ê°™ì€ ê²ƒë“¤ì„ ê³„ì† ë°›ì„ ìˆ˜ ìˆë„ë¡ ë„ì™€ì£¼ë©° ì¹˜ë£Œì˜ ì—°ì†ì„±ì„ ë§Œë“¤ì–´ë‚¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œì˜ ê¸°íšŒëŠ” ë§ ê·¸ëŒ€ë¡œ ë¬´í•œí•˜ë‹¤ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì €ëŠ” ì²« ë²ˆì§¸ ë°œí‘œë¥¼ í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤. ì €í¬ê°€ í—¬ìŠ¤ì¼€ì–´ ì—…ê³„ì—ì„œ ê°€ì¥ ì˜í–¥ë ¥ ìˆëŠ” íšŒì‚¬ ì¤‘ í•˜ë‚˜ì´ì, ì„¸ê³„ ìµœëŒ€ì˜ ì„ìƒì—°êµ¬ ì„œë¹„ìŠ¤, ìƒì—… ì¸í…”ë¦¬ì „ìŠ¤, ê·¸ë¦¬ê³  í—¬ìŠ¤ì¼€ì–´ ë¶„ì„ íšŒì‚¬ì¸ IQVIAì™€ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºê²Œ ë˜ì–´ ì •ë§ ê¸°ì©ë‹ˆë‹¤.</td></tr>
<tr><td>IQVIA and NVIDIA are going to be working together to take the amazing health data network that IQVIA has built over the last couple of decades. They've got a unique database where they can put that to work and build custom proprietary AI models using NVIDIA's AI foundry services on our DGX Cloud capacity, all the way through to the entire AI life cycle, just like I showed you with TJ, and assemble agentic platforms and workflows to address some of the most critical areas of work. In fact, some of the areas that we're going to work on first is in clinical trials. How can we accelerate the pace of clinical trials? How can we use this to reduce the administrative burden of clinical trials?</td><td>IQVIAì™€ NVIDIAëŠ” í˜‘ë ¥í•˜ì—¬ IQVIAê°€ ì§€ë‚œ ìˆ˜ì‹­ ë…„ê°„ êµ¬ì¶•í•´ì˜¨ ë†€ë¼ìš´ í—¬ìŠ¤ ë°ì´í„° ë„¤íŠ¸ì›Œí¬ë¥¼ í™œìš©í•  ì˜ˆì •ì…ë‹ˆë‹¤. IQVIAëŠ” ê³ ìœ í•œ ë°ì´í„°ë² ì´ìŠ¤ë¥¼ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ë¥¼ í™œìš©í•˜ì—¬ NVIDIAì˜ DGX Cloud ìš©ëŸ‰ì—ì„œ ì œê³µë˜ëŠ” AI íŒŒìš´ë“œë¦¬ ì„œë¹„ìŠ¤ë¥¼ ì´ìš©í•´ ë§ì¶¤í˜• ë…ì  AI ëª¨ë¸ì„ êµ¬ì¶•í•  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì œê°€ TJì™€ í•¨ê»˜ ë³´ì—¬ë“œë¦° ê²ƒì²˜ëŸ¼ ì „ì²´ AI ë¼ì´í”„ì‚¬ì´í´ì— ê±¸ì³ ì§„í–‰ë˜ë©°, ê°€ì¥ ì¤‘ìš”í•œ ì—…ë¬´ ì˜ì—­ë“¤ì„ ë‹¤ë£¨ê¸° ìœ„í•œ ì—ì´ì „í‹± í”Œë«í¼ê³¼ ì›Œí¬í”Œë¡œìš°ë¥¼ êµ¬ì„±í•˜ê²Œ ë©ë‹ˆë‹¤. ì‹¤ì œë¡œ ìš°ë¦¬ê°€ ë¨¼ì € ì‘ì—…í•  ì˜ì—­ ì¤‘ ì¼ë¶€ëŠ” ì„ìƒì‹œí—˜ ë¶„ì•¼ì…ë‹ˆë‹¤. ì–´ë–»ê²Œ í•˜ë©´ ì„ìƒì‹œí—˜ì˜ ì†ë„ë¥¼ ê°€ì†í™”í•  ìˆ˜ ìˆì„ê¹Œìš”? ì–´ë–»ê²Œ í•˜ë©´ ì´ë¥¼ í™œìš©í•˜ì—¬ ì„ìƒì‹œí—˜ì˜ í–‰ì •ì  ë¶€ë‹´ì„ ì¤„ì¼ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>All of this in order to get medicines to patients faster and really imagine how we're going to see a different clinical trial process as well as the growth and the ability to get medicines to market. This is an incredibly exciting partnership and Bhavik is here. Thank you for flying in. We're delighted to embark on building on top of their IQVIA Connected Intelligence, through all of the NVIDIA AI Enterprise from foundry services, NeMo services, agentic services to deploy agents of all kinds through to their healthcare grade AI solutions and services to bring to their over 10,000 customers across 100 countries, incredible. Okay. Let's switch gears to computer-aided drug discovery.</td><td>ì´ ëª¨ë“  ê²ƒì€ í™˜ìë“¤ì—ê²Œ ë” ë¹ ë¥´ê²Œ ì˜ì•½í’ˆì„ ì „ë‹¬í•˜ê¸° ìœ„í•œ ê²ƒì´ë©°, ì„ìƒì‹œí—˜ ê³¼ì •ì´ ì–´ë–»ê²Œ ë‹¬ë¼ì§ˆì§€, ê·¸ë¦¬ê³  ì˜ì•½í’ˆì„ ì‹œì¥ì— ì¶œì‹œí•˜ëŠ” ì„±ì¥ê³¼ ëŠ¥ë ¥ì„ ì–´ë–»ê²Œ ë³´ê²Œ ë ì§€ ì •ë§ ìƒìƒí•´ë³´ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ê²ƒì€ ë§¤ìš° í¥ë¯¸ì§„ì§„í•œ íŒŒíŠ¸ë„ˆì‹­ì´ë©° ë°”ë¹…ì´ ì—¬ê¸° ì™€ ìˆìŠµë‹ˆë‹¤. ë¹„í–‰ê¸°ë¡œ ì™€ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê·¸ë“¤ì˜ IQVIA Connected Intelligenceë¥¼ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì¶•í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. íŒŒìš´ë“œë¦¬ ì„œë¹„ìŠ¤, NeMo ì„œë¹„ìŠ¤, ëª¨ë“  ì¢…ë¥˜ì˜ ì—ì´ì „íŠ¸ë¥¼ ë°°í¬í•˜ëŠ” ì—ì´ì „í‹± ì„œë¹„ìŠ¤ë¶€í„° í—¬ìŠ¤ì¼€ì–´ ë“±ê¸‰ AI ì†”ë£¨ì…˜ ë° ì„œë¹„ìŠ¤ì— ì´ë¥´ê¸°ê¹Œì§€ ëª¨ë“  NVIDIA AI Enterpriseë¥¼ í†µí•´ 100ê°œêµ­ì— ê±¸ì¹œ 10,000ëª… ì´ìƒì˜ ê³ ê°ë“¤ì—ê²Œ ì œê³µí•  ì˜ˆì •ì…ë‹ˆë‹¤. ì •ë§ ë†€ëìŠµë‹ˆë‹¤. ì, ì´ì œ ì»´í“¨í„° ì§€ì› ì‹ ì•½ ê°œë°œë¡œ í™”ì œë¥¼ ë°”ê¿”ë³´ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We talked last year how we would love to turn the word discovery into design. I think last year's Nobel Prize, congratulations to David Baker, Demis Hassabis and John Jumper of the Nobel Prize in Chemistry for AlphaFold and its profound impact in protein structure. And this is a testament to say how important this capability is going to be for drug discovery and biology understanding in the future. It is on a tear. We continue to see new models of all kinds. Our fantastic partners are building models like Immix, Neuroplexor3, MIT, the Geneo Clinic and Genesis Therapeutics with their Bolt 1, Evolutionary Scale and their ESM3, these are multimodal.</td><td>ì‘ë…„ì— ìš°ë¦¬ê°€ 'ë°œê²¬(discovery)'ì´ë¼ëŠ” ë‹¨ì–´ë¥¼ 'ì„¤ê³„(design)'ë¡œ ë°”ê¾¸ê³  ì‹¶ë‹¤ê³  ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ì‘ë…„ ë…¸ë²¨ìƒ, AlphaFoldì™€ ë‹¨ë°±ì§ˆ êµ¬ì¡°ì— ë¯¸ì¹œ ê¹Šì€ ì˜í–¥ìœ¼ë¡œ ë…¸ë²¨ í™”í•™ìƒì„ ìˆ˜ìƒí•œ David Baker, Demis Hassabis, John Jumperì—ê²Œ ì¶•í•˜ë¥¼ ë“œë¦½ë‹ˆë‹¤. ì´ëŠ” ì´ëŸ¬í•œ ì—­ëŸ‰ì´ í–¥í›„ ì‹ ì•½ ë°œê²¬ê³¼ ìƒë¬¼í•™ì  ì´í•´ì— ì–¼ë§ˆë‚˜ ì¤‘ìš”í• ì§€ë¥¼ ë³´ì—¬ì£¼ëŠ” ì¦ê±°ì…ë‹ˆë‹¤. ì´ ë¶„ì•¼ëŠ” ê¸‰ì†ë„ë¡œ ë°œì „í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ ëª¨ë“  ì¢…ë¥˜ì˜ ìƒˆë¡œìš´ ëª¨ë¸ë“¤ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ í›Œë¥­í•œ íŒŒíŠ¸ë„ˆë“¤ì´ Immix, Neuroplexor3, MIT, Geneo Clinic, ê·¸ë¦¬ê³  Bolt 1ì„ ê°œë°œí•œ Genesis Therapeutics, ESM3ë¥¼ ê°œë°œí•œ Evolutionary Scaleê³¼ ê°™ì€ ëª¨ë¸ë“¤ì„ êµ¬ì¶•í•˜ê³  ìˆìœ¼ë©°, ì´ë“¤ì€ ëª¨ë‘ ë©€í‹°ëª¨ë‹¬ ëª¨ë¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>They can work with DNA, RNA, proteins, ligands, really understanding much more about their interactions and transforming virtual screening in incredible new ways. The NVIDIA BioNeMo platform is a way of democratizing this. We have an end-to-end platform for, again, the entire life cycle, starting from the training of models. Every single tech bio, biotech, pharma company has wet labs running approximately 24 hours a day, generating very, very rich data. That data needs to be built into intelligence. And those are NVIDIA NIMs and micro services. We've also curated a whole bunch, over a dozen now of micro services that can be used as APIs. They're as simple as an API call.</td><td>ê·¸ë“¤ì€ DNA, RNA, ë‹¨ë°±ì§ˆ, ë¦¬ê°„ë“œë¥¼ ë‹¤ë£° ìˆ˜ ìˆìœ¼ë©°, ì´ë“¤ ê°„ì˜ ìƒí˜¸ì‘ìš©ì„ í›¨ì”¬ ë” ê¹Šì´ ì´í•´í•˜ê³  ê°€ìƒ ìŠ¤í¬ë¦¬ë‹ì„ ë†€ë¼ìš´ ìƒˆë¡œìš´ ë°©ì‹ìœ¼ë¡œ ë³€í™”ì‹œí‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. NVIDIA BioNeMo í”Œë«í¼ì€ ì´ë¥¼ ë¯¼ì£¼í™”í•˜ëŠ” ë°©ë²•ì…ë‹ˆë‹¤. ì €í¬ëŠ” ëª¨ë¸ í›ˆë ¨ë¶€í„° ì‹œì‘í•˜ì—¬ ì „ì²´ ìƒëª…ì£¼ê¸°ë¥¼ ìœ„í•œ ì—”ë“œíˆ¬ì—”ë“œ í”Œë«í¼ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ëª¨ë“  í…Œí¬ë°”ì´ì˜¤, ë°”ì´ì˜¤í…Œí¬, ì œì•½íšŒì‚¬ë“¤ì€ í•˜ë£¨ ì•½ 24ì‹œê°„ ë™ì•ˆ ì›»ë©ì„ ìš´ì˜í•˜ë©° ë§¤ìš° í’ë¶€í•œ ë°ì´í„°ë¥¼ ìƒì„±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë°ì´í„°ëŠ” ì¸í…”ë¦¬ì „ìŠ¤ë¡œ êµ¬ì¶•ë˜ì–´ì•¼ í•©ë‹ˆë‹¤. ê·¸ê²ƒì´ ë°”ë¡œ NVIDIA NIMê³¼ ë§ˆì´í¬ë¡œì„œë¹„ìŠ¤ì…ë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” APIë¡œ ì‚¬ìš©í•  ìˆ˜ ìˆëŠ” ë§ˆì´í¬ë¡œì„œë¹„ìŠ¤ë¥¼ í˜„ì¬ 12ê°œ ì´ìƒ íë ˆì´ì…˜í–ˆìŠµë‹ˆë‹¤. ì´ë“¤ì€ API í˜¸ì¶œë§Œí¼ ê°„ë‹¨í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Introduce a protein sequence, outcomes a 3D structure. But then the other part of the -- new part of the platform is NVIDIA BioNeMo blueprints. Again, these are reference applications. This is an example of how can you do virtual screening by assembling three different generative AI applications to do full generative AI virtual screening at unprecedented scale. We are introducing here today and it's available on ai.nvidia.com, one of our own foundation models called, GenMol. This is an evolution. We started in 2020, I think it was, with AstraZeneca and our molecular generation, MolMIM last year and next generation here now with GenMol, which is goal-directed molecular generation.</td><td>ë‹¨ë°±ì§ˆ ì„œì—´ì„ ì…ë ¥í•˜ë©´ 3D êµ¬ì¡°ë¥¼ ì¶œë ¥í•©ë‹ˆë‹¤. ê·¸ëŸ°ë° í”Œë«í¼ì˜ ë˜ ë‹¤ë¥¸ ìƒˆë¡œìš´ ë¶€ë¶„ì€ NVIDIA BioNeMo ë¸”ë£¨í”„ë¦°íŠ¸ì…ë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ê²ƒë“¤ì€ ì°¸ì¡° ì• í”Œë¦¬ì¼€ì´ì…˜ì…ë‹ˆë‹¤. ì´ëŠ” ì„¸ ê°€ì§€ ì„œë¡œ ë‹¤ë¥¸ ìƒì„±í˜• AI ì• í”Œë¦¬ì¼€ì´ì…˜ì„ ì¡°í•©í•˜ì—¬ ì „ë¡€ ì—†ëŠ” ê·œëª¨ë¡œ ì™„ì „í•œ ìƒì„±í˜• AI ê°€ìƒ ìŠ¤í¬ë¦¬ë‹ì„ ìˆ˜í–‰í•˜ëŠ” ë°©ë²•ì˜ ì˜ˆì‹œì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì—¬ê¸°ì„œ ì†Œê°œí•˜ê³  ai.nvidia.comì—ì„œ ì´ìš© ê°€ëŠ¥í•œ ê²ƒì€ GenMolì´ë¼ê³  ë¶ˆë¦¬ëŠ” ì €í¬ ìì²´ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ì´ëŠ” ì§„í™”ì˜ ê²°ê³¼ë¬¼ì…ë‹ˆë‹¤. 2020ë…„ê²½ë¶€í„° AstraZenecaì™€ í•¨ê»˜ ë¶„ì ìƒì„± ì‘ì—…ì„ ì‹œì‘í–ˆê³ , ì‘ë…„ì—ëŠ” MolMIMì„, ê·¸ë¦¬ê³  ì§€ê¸ˆ ì—¬ê¸°ì„œ ì°¨ì„¸ëŒ€ GenMolì„ ì„ ë³´ì´ëŠ”ë°, ì´ëŠ” ëª©í‘œ ì§€í–¥ì  ë¶„ì ìƒì„± ëª¨ë¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So this is where you can introduce your own objectives and it can generate molecules. And it generalizes across really critical workflows from hit to lead workflows, as you can see here with generative de novo molecule design and Motif extension upon many more. Our NVIDIA BioNeMo platform continues to expand. And as I said, these Generative AI models have applicability from beginning to end, all the way from target discovery all the way through to clinical trials. And we continue to build these micro services as easy ways to integrate this capability into processes and drug discovery platforms of all kinds, right next to the wet lab serving as your dry lab.</td><td>ë”°ë¼ì„œ ì—¬ê¸°ì„œ ê³ ìœ í•œ ëª©í‘œë¥¼ ë„ì…í•  ìˆ˜ ìˆìœ¼ë©°, ì´ë¥¼ í†µí•´ ë¶„ìë¥¼ ìƒì„±í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” ì—¬ê¸°ì„œ ë³´ì‹œëŠ” ë°”ì™€ ê°™ì´ ìƒì„±í˜• ë“œ ë…¸ë³´ ë¶„ì ì„¤ê³„(generative de novo molecule design)ì™€ ëª¨í‹°í”„ í™•ì¥(Motif extension) ë“±ì„ í¬í•¨í•œ íˆíŠ¸ íˆ¬ ë¦¬ë“œ(hit to lead) ì›Œí¬í”Œë¡œìš°ì™€ ê°™ì€ ë§¤ìš° ì¤‘ìš”í•œ ì›Œí¬í”Œë¡œìš° ì „ë°˜ì— ê±¸ì³ ì¼ë°˜í™”ë©ë‹ˆë‹¤.<br><br>ì €í¬ NVIDIA BioNeMo í”Œë«í¼ì€ ì§€ì†ì ìœ¼ë¡œ í™•ì¥ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œê°€ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì´ëŸ¬í•œ ìƒì„±í˜• AI ëª¨ë¸ë“¤ì€ íƒ€ê²Ÿ ë°œê²¬ë¶€í„° ì„ìƒì‹œí—˜ì— ì´ë¥´ê¸°ê¹Œì§€ ì²˜ìŒë¶€í„° ëê¹Œì§€ ì ìš© ê°€ëŠ¥ì„±ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ëŸ¬í•œ ë§ˆì´í¬ë¡œì„œë¹„ìŠ¤ë“¤ì„ ëª¨ë“  ì¢…ë¥˜ì˜ í”„ë¡œì„¸ìŠ¤ì™€ ì‹ ì•½ ê°œë°œ í”Œë«í¼ì— ì‰½ê²Œ í†µí•©í•  ìˆ˜ ìˆëŠ” ë°©ë²•ìœ¼ë¡œ ê³„ì† êµ¬ì¶•í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ìŠµì‹ ì‹¤í—˜ì‹¤(wet lab) ë°”ë¡œ ì˜†ì—ì„œ ê±´ì‹ ì‹¤í—˜ì‹¤(dry lab) ì—­í• ì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we're building these blueprints, which you can essentially think of as drug discovery assistants. The blueprints, we -- last year in 2024, we introduced the virtual screening blueprint. We're continuing to evolve it, make it smarter and make it faster. And then we, today, are introducing our protein design assistant for protein binder design. So we have small molecule on the left, large molecule on the right, and this is so that we can essentially de novo develop new proteins. Let me show you how it works. [Video Presentation]<br><br>Incredible stuff. I'm excited to announce our second announcement.</td><td>ê·¸ë¦¬ê³  ì €í¬ëŠ” ë³¸ì§ˆì ìœ¼ë¡œ ì‹ ì•½ ë°œê²¬ ì–´ì‹œìŠ¤í„´íŠ¸ë¼ê³  ìƒê°í•˜ì‹¤ ìˆ˜ ìˆëŠ” ì´ëŸ¬í•œ ë¸”ë£¨í”„ë¦°íŠ¸ë“¤ì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¸”ë£¨í”„ë¦°íŠ¸ì™€ ê´€ë ¨í•´ì„œëŠ” -- ì‘ë…„ 2024ë…„ì— ê°€ìƒ ìŠ¤í¬ë¦¬ë‹ ë¸”ë£¨í”„ë¦°íŠ¸ë¥¼ ë„ì…í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ë¥¼ ì§€ì†ì ìœ¼ë¡œ ë°œì „ì‹œì¼œ ë”ìš± ìŠ¤ë§ˆíŠ¸í•˜ê³  ë¹ ë¥´ê²Œ ë§Œë“¤ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì €í¬ëŠ” ë‹¨ë°±ì§ˆ ê²°í•©ì²´ ì„¤ê³„ë¥¼ ìœ„í•œ ë‹¨ë°±ì§ˆ ì„¤ê³„ ì–´ì‹œìŠ¤í„´íŠ¸ë¥¼ ì†Œê°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì™¼ìª½ì—ëŠ” ì €ë¶„ì, ì˜¤ë¥¸ìª½ì—ëŠ” ê³ ë¶„ìê°€ ìˆìœ¼ë©°, ì´ë¥¼ í†µí•´ ë³¸ì§ˆì ìœ¼ë¡œ ìƒˆë¡œìš´ ë‹¨ë°±ì§ˆì„ ì™„ì „íˆ ìƒˆë¡­ê²Œ ê°œë°œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì–´ë–»ê²Œ ì‘ë™í•˜ëŠ”ì§€ ë³´ì—¬ë“œë¦¬ê² ìŠµë‹ˆë‹¤. [ë¹„ë””ì˜¤ í”„ë ˆì  í…Œì´ì…˜]<br><br>ì •ë§ ë†€ë¼ìš´ ë‚´ìš©ì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ ë°œí‘œë¥¼ í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤.</td></tr>
<tr><td>We are working with the Arc Institute on the development of true foundation models for biology. As you know, the foundation models in language are hitting the trillions of parameters. In biology, we're sitting in the tens of billions, approaching 100 billion parameters. There's a lot of work to do. In fact, the Arc Institute has the charter, the mission of wanting to understand disease at a much deeper level. And where else to do that than in the source code of biology itself and DNA, RNA, and proteins. And so we're working together to build very large-scale foundation models. We're going to -- we're using the NVIDIA DGX Cloud infrastructure, BioNeMo.</td><td>ì €í¬ëŠ” Arc Instituteì™€ í•¨ê»˜ ìƒë¬¼í•™ì„ ìœ„í•œ ì§„ì •í•œ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ ê°œë°œì— í˜‘ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼, ì–¸ì–´ ë¶„ì•¼ì˜ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ë“¤ì€ ìˆ˜ì¡° ê°œì˜ ë§¤ê°œë³€ìˆ˜ì— ë„ë‹¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒë¬¼í•™ ë¶„ì•¼ì—ì„œëŠ” í˜„ì¬ ìˆ˜ë°±ì–µ ê°œ ìˆ˜ì¤€ì—ì„œ 1,000ì–µ ê°œ ë§¤ê°œë³€ìˆ˜ì— ê·¼ì ‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•„ì§ í•´ì•¼ í•  ì¼ì´ ë§ìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ Arc InstituteëŠ” ì§ˆë³‘ì„ í›¨ì”¬ ë” ê¹Šì€ ìˆ˜ì¤€ì—ì„œ ì´í•´í•˜ê³ ì í•˜ëŠ” ì‚¬ëª…ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìƒë¬¼í•™ì˜ ì†ŒìŠ¤ ì½”ë“œ ìì²´ì¸ DNA, RNA, ê·¸ë¦¬ê³  ë‹¨ë°±ì§ˆë³´ë‹¤ ë” ì í•©í•œ ê³³ì´ ì–´ë”” ìˆê² ìŠµë‹ˆê¹Œ. ë”°ë¼ì„œ ì €í¬ëŠ” í•¨ê»˜ ë§¤ìš° ëŒ€ê·œëª¨ì˜ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” NVIDIA DGX Cloud ì¸í”„ë¼ì™€ BioNeMoë¥¼ ì‚¬ìš©í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>All of the models that we develop are -- they're going to be built upon last year's Arc Institute's breakthrough with their EVO model, which, again, is a multimodal model for biology. And the Arc Institute is a really unique place. They have really invested in the funding of people versus projects. And I think there's a really profound thing that needs to be considered in science. In order for science to scale, we know we need machine learning. In order to do machine learning, you need to have machines. And so this is really a shift that needs to happen in the scientific community. We're working with Arc to deeply understand that.</td><td>ì €í¬ê°€ ê°œë°œí•˜ëŠ” ëª¨ë“  ëª¨ë¸ë“¤ì€ ì‘ë…„ Arc Instituteì˜ EVO ëª¨ë¸ í˜ì‹ ì„ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì¶•ë  ì˜ˆì •ì…ë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, ì´ëŠ” ìƒë¬¼í•™ì„ ìœ„í•œ ë©€í‹°ëª¨ë‹¬ ëª¨ë¸ì…ë‹ˆë‹¤. Arc InstituteëŠ” ì •ë§ ë…íŠ¹í•œ ê³³ì…ë‹ˆë‹¤. ê·¸ë“¤ì€ í”„ë¡œì íŠ¸ê°€ ì•„ë‹Œ ì¸ì¬ì— ëŒ€í•œ íˆ¬ìì— ì§„ì •ìœ¼ë¡œ ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê³¼í•™ ë¶„ì•¼ì—ì„œ ì •ë§ ì‹¬ë„ ìˆê²Œ ê³ ë ¤í•´ì•¼ í•  ì¤‘ìš”í•œ ì ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê³¼í•™ì´ í™•ì¥ë˜ê¸° ìœ„í•´ì„œëŠ” ë¨¸ì‹ ëŸ¬ë‹ì´ í•„ìš”í•˜ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë¨¸ì‹ ëŸ¬ë‹ì„ ìˆ˜í–‰í•˜ê¸° ìœ„í•´ì„œëŠ” ê¸°ê³„ê°€ ìˆì–´ì•¼ í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŠ” ê³¼í•™ê³„ì—ì„œ ì¼ì–´ë‚˜ì•¼ í•˜ëŠ” ì§„ì •í•œ íŒ¨ëŸ¬ë‹¤ì„ ì „í™˜ì…ë‹ˆë‹¤. ì €í¬ëŠ” Arcì™€ í˜‘ë ¥í•˜ì—¬ ì´ë¥¼ ê¹Šì´ ì´í•´í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Everything that we build, we will be putting back into the open source into BioNeMo. And you're going to see a lot of that work come to fruition over the next several months and throughout 2025. So keep a lookout for future announcements with the Arc Institute and NVIDIA. As I say, the source code of humans and biology is in genomics. We've been working with amazing partners in the genomics industry, helping to build these regional population-specific genomics data sets. And the world now is really rushing to determine their sovereign AI strategies. We've really helped to lay the foundation, giving the capabilities to generate this data.</td><td>ìš°ë¦¬ê°€ êµ¬ì¶•í•˜ëŠ” ëª¨ë“  ê²ƒì€ BioNeMoë¥¼ í†µí•´ ì˜¤í”ˆ ì†ŒìŠ¤ë¡œ ë‹¤ì‹œ ì œê³µë  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•ìœ¼ë¡œ ëª‡ ë‹¬ê°„ ê·¸ë¦¬ê³  2025ë…„ ë‚´ë‚´ ì´ëŸ¬í•œ ì‘ì—…ì˜ ë§ì€ ì„±ê³¼ë¥¼ ë³´ì‹œê²Œ ë  ê²ƒì…ë‹ˆë‹¤. Arc Instituteì™€ NVIDIAì˜ í–¥í›„ ë°œí‘œë¥¼ ì£¼ëª©í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë ¸ë“¯ì´, ì¸ê°„ê³¼ ìƒë¬¼í•™ì˜ ì†ŒìŠ¤ ì½”ë“œëŠ” ìœ ì „ì²´í•™ì— ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìœ ì „ì²´í•™ ì—…ê³„ì˜ ë†€ë¼ìš´ íŒŒíŠ¸ë„ˆë“¤ê³¼ í˜‘ë ¥í•˜ì—¬ ì´ëŸ¬í•œ ì§€ì—­ë³„, ì¸êµ¬ë³„ íŠ¹í™” ìœ ì „ì²´ ë°ì´í„°ì…‹ êµ¬ì¶•ì„ ì§€ì›í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í˜„ì¬ ì „ ì„¸ê³„ëŠ” ìêµ­ì˜ ì£¼ê¶Œ AI ì „ëµì„ ìˆ˜ë¦½í•˜ê¸° ìœ„í•´ ì •ë§ ì„œë‘ë¥´ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ë°ì´í„°ë¥¼ ìƒì„±í•  ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì„ ì œê³µí•¨ìœ¼ë¡œì¨ ê¸°ë°˜ì„ ë§ˆë ¨í•˜ëŠ” ë° ì‹¤ì§ˆì ìœ¼ë¡œ ë„ì›€ì„ ì£¼ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But we need to, by working with the Arc Institute and building new foundation models, we need to give the world not only the ability to generate the data but to derive insights from this data. And so I'm extremely pleased to announce our third announcement for the day, which is our partnership with Illumina. Illumina is a world leader in genomics. We're going to be working together by combining the Illumina sequencing platforms, NVIDIA's NVIDIA Clara tool set, everything from our multiomics BioNeMo for foundation models in biology, RAPIDS for data science acceleration, MONAI for cell imaging and other workflows into the Illumina connected analytics.</td><td>í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” Arc Instituteì™€ì˜ í˜‘ë ¥ì„ í†µí•´ ìƒˆë¡œìš´ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì„ êµ¬ì¶•í•¨ìœ¼ë¡œì¨, ì„¸ìƒì— ë°ì´í„°ë¥¼ ìƒì„±í•˜ëŠ” ëŠ¥ë ¥ë¿ë§Œ ì•„ë‹ˆë¼ ì´ ë°ì´í„°ë¡œë¶€í„° ì¸ì‚¬ì´íŠ¸ë¥¼ ë„ì¶œí•˜ëŠ” ëŠ¥ë ¥ì„ ì œê³µí•´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜¤ëŠ˜ ì„¸ ë²ˆì§¸ ë°œí‘œë¥¼ í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤. ë°”ë¡œ Illuminaì™€ì˜ íŒŒíŠ¸ë„ˆì‹­ì…ë‹ˆë‹¤. IlluminaëŠ” ìœ ì „ì²´í•™ ë¶„ì•¼ì˜ ì„¸ê³„ì  ì„ ë„ê¸°ì—…ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” Illumina ì‹œí€€ì‹± í”Œë«í¼ê³¼ NVIDIAì˜ NVIDIA Clara íˆ´ì…‹ì„ ê²°í•©í•˜ì—¬ í˜‘ë ¥í•  ì˜ˆì •ì…ë‹ˆë‹¤. ìƒë¬¼í•™ ë¶„ì•¼ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì„ ìœ„í•œ ë©€í‹°ì˜¤ë¯¹ìŠ¤ BioNeMoë¶€í„° ë°ì´í„° ì‚¬ì´ì–¸ìŠ¤ ê°€ì†í™”ë¥¼ ìœ„í•œ RAPIDS, ì„¸í¬ ì´ë¯¸ì§•ì„ ìœ„í•œ MONAI ë° ê¸°íƒ€ ì›Œí¬í”Œë¡œìš°ê¹Œì§€ ëª¨ë“  ê²ƒì„ Illumina ì»¤ë„¥í‹°ë“œ ì• ë„ë¦¬í‹±ìŠ¤ì— í†µí•©í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>This partnership is going to be fantastic. One of the first things we're going to do is we're going to take Dragon, the industry standard of secondary analysis, bring it to the GPU. We're going to do that so we can expand the market so that Dragon can be deployed wherever there are NVIDIA GPUs in every public cloud, in every sovereign nation, in every data center and expand the market.</td><td>ì´ íŒŒíŠ¸ë„ˆì‹­ì€ ì •ë§ í™˜ìƒì ì¼ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ ê°€ì¥ ë¨¼ì € í•  ì¼ ì¤‘ í•˜ë‚˜ëŠ” 2ì°¨ ë¶„ì„ì˜ ì—…ê³„ í‘œì¤€ì¸ Dragonì„ GPUë¡œ ê°€ì ¸ì˜¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì‹œì¥ì„ í™•ì¥í•˜ì—¬ Dragonì´ ëª¨ë“  í¼ë¸”ë¦­ í´ë¼ìš°ë“œ, ëª¨ë“  ì£¼ê¶Œ êµ­ê°€, ëª¨ë“  ë°ì´í„° ì„¼í„°ì—ì„œ NVIDIA GPUê°€ ìˆëŠ” ê³³ì´ë¼ë©´ ì–´ë””ë“  ë°°í¬ë  ìˆ˜ ìˆë„ë¡ í•˜ê³  ì‹œì¥ì„ í™•ì¥í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And then we're going to work together to build new applications in the Illumina connected analytics, bringing genomics foundation models, bringing single-cell applications that are essentially real time at very, very large scale and expand the genomics accessibility in utility into new markets like drug discovery. We still have so much to learn about the foundational building blocks of biology.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” í•¨ê»˜ í˜‘ë ¥í•˜ì—¬ Illumina ì»¤ë„¥í‹°ë“œ ì• ë„ë¦¬í‹±ìŠ¤ì—ì„œ ìƒˆë¡œìš´ ì• í”Œë¦¬ì¼€ì´ì…˜ì„ êµ¬ì¶•í•  ì˜ˆì •ì…ë‹ˆë‹¤. ìœ ì „ì²´í•™ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì„ ë„ì…í•˜ê³ , ë§¤ìš° ëŒ€ê·œëª¨ì—ì„œ ë³¸ì§ˆì ìœ¼ë¡œ ì‹¤ì‹œê°„ìœ¼ë¡œ ì‘ë™í•˜ëŠ” ë‹¨ì¼ì„¸í¬ ì• í”Œë¦¬ì¼€ì´ì…˜ì„ êµ¬ì¶•í•˜ë©°, ì‹ ì•½ ê°œë°œê³¼ ê°™ì€ ìƒˆë¡œìš´ ì‹œì¥ìœ¼ë¡œ ìœ ì „ì²´í•™ì˜ ì ‘ê·¼ì„±ê³¼ ìœ ìš©ì„±ì„ í™•ì¥í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì—¬ì „íˆ ìƒë¬¼í•™ì˜ ê¸°ì´ˆ êµ¬ì„± ìš”ì†Œì— ëŒ€í•´ ë°°ì›Œì•¼ í•  ê²ƒì´ ë„ˆë¬´ë‚˜ ë§ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>It's in the amazing data that Illumina is generating, and now we're going to be working together to build those tools, build those capabilities and expand the genomics market into the next generation, into Generative AI genomics, and all the way to making it more accessible to the research community, to the biopharma and biotech community, and even expanding it into clinical and research clinical applications. Super excited about this partnership and we will be announcing more opportunities here as the time goes on. Okay. Last chapter. Here we go. Every sensor, every patient room, every hospital will integrate physical AI. It's a new concept.</td><td>ì¼ë£¨ë¯¸ë‚˜ê°€ ìƒì„±í•˜ê³  ìˆëŠ” ë†€ë¼ìš´ ë°ì´í„°ì— ìˆìœ¼ë©°, ì´ì œ ìš°ë¦¬ëŠ” í•¨ê»˜ í˜‘ë ¥í•˜ì—¬ ì´ëŸ¬í•œ ë„êµ¬ë“¤ì„ êµ¬ì¶•í•˜ê³ , ì´ëŸ¬í•œ ì—­ëŸ‰ë“¤ì„ êµ¬ì¶•í•˜ë©°, ìœ ì „ì²´í•™ ì‹œì¥ì„ ì°¨ì„¸ëŒ€ë¡œ, ìƒì„±í˜• AI ìœ ì „ì²´í•™ìœ¼ë¡œ í™•ì¥í•˜ê³ , ì—°êµ¬ ì»¤ë®¤ë‹ˆí‹°, ë°”ì´ì˜¤íŒŒë§ˆ ë° ë°”ì´ì˜¤í…Œí¬ ì»¤ë®¤ë‹ˆí‹°ì— ë”ìš± ì ‘ê·¼ ê°€ëŠ¥í•˜ê²Œ ë§Œë“¤ê³ , ì‹¬ì§€ì–´ ì„ìƒ ë° ì—°êµ¬ ì„ìƒ ì‘ìš© ë¶„ì•¼ë¡œê¹Œì§€ í™•ì¥í•  ê²ƒì…ë‹ˆë‹¤. ì´ë²ˆ íŒŒíŠ¸ë„ˆì‹­ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ë” ë§ì€ ê¸°íšŒë“¤ì„ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ì¢‹ìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ ì¥ì…ë‹ˆë‹¤. ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ëª¨ë“  ì„¼ì„œ, ëª¨ë“  í™˜ìì‹¤, ëª¨ë“  ë³‘ì›ì´ ë¬¼ë¦¬ì  AIë¥¼ í†µí•©í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ìƒˆë¡œìš´ ê°œë…ì…ë‹ˆë‹¤.</td></tr>
<tr><td>But the simple way to think about physical AI is that it understands the physical world. It understands the environment. It understands that you're taking this picture right now, and it thinks, I made a good slide. But the real opportunity here is healthcare delivery is a very labor-intensive place. And we have thousands of hospitals around the world. We have hundreds, hundreds of thousands, excuse me, we have hundreds of thousands of operating rooms. We have millions of patient rooms and billions of devices. And I said, each one of them is going to be robotic. We have been building the three computers to realize physical AI.</td><td>í•˜ì§€ë§Œ ë¬¼ë¦¬ì  AIì— ëŒ€í•´ ê°„ë‹¨íˆ ìƒê°í•´ë³´ë©´, ì´ëŠ” ë¬¼ë¦¬ì  ì„¸ê³„ë¥¼ ì´í•´í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. í™˜ê²½ì„ ì´í•´í•©ë‹ˆë‹¤. ì§€ê¸ˆ ì—¬ëŸ¬ë¶„ì´ ì´ ì‚¬ì§„ì„ ì°ê³  ìˆë‹¤ëŠ” ê²ƒì„ ì´í•´í•˜ê³ , 'ì¢‹ì€ ìŠ¬ë¼ì´ë“œë¥¼ ë§Œë“¤ì—ˆêµ¬ë‚˜'ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì—¬ê¸°ì„œ ì§„ì •í•œ ê¸°íšŒëŠ” ì˜ë£Œ ì„œë¹„ìŠ¤ ì œê³µì´ ë§¤ìš° ë…¸ë™ì§‘ì•½ì ì¸ ë¶„ì•¼ë¼ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì „ ì„¸ê³„ì— ìˆ˜ì²œ ê°œì˜ ë³‘ì›ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìˆ˜ì‹­ë§Œ ê°œì˜... ì£„ì†¡í•©ë‹ˆë‹¤, ìˆ˜ì‹­ë§Œ ê°œì˜ ìˆ˜ìˆ ì‹¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìˆ˜ë°±ë§Œ ê°œì˜ í™˜ìì‹¤ê³¼ ìˆ˜ì‹­ì–µ ê°œì˜ ê¸°ê¸°ë“¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œê°€ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì´ë“¤ ê°ê°ì´ ë¡œë´‡í™”ë  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¬¼ë¦¬ì  AIë¥¼ êµ¬í˜„í•˜ê¸° ìœ„í•´ ì„¸ ê°€ì§€ ì»´í“¨í„°ë¥¼ êµ¬ì¶•í•´ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The first computer that you well know us for is the computer that runs the real-time AI. Think about what we've done for self-driving cars, the car that lives in the computer, or think about the embedded products that lives inside the surgical robot. That's the robot brain. That's the brain in the robot. And the other computer, you also know us for, that's to develop the AI, NVIDIA DGX for NVIDIA AI. But we've been missing the third part of the trinity, and that is Omniverse for developing virtual worlds that are grounded in physics.</td><td>ì €í¬ê°€ ì˜ ì•Œë ¤ì§„ ì²« ë²ˆì§¸ ì»´í“¨í„°ëŠ” ì‹¤ì‹œê°„ AIë¥¼ êµ¬ë™í•˜ëŠ” ì»´í“¨í„°ì…ë‹ˆë‹¤. ììœ¨ì£¼í–‰ì°¨ë¥¼ ìœ„í•´ ì €í¬ê°€ í•´ì˜¨ ì¼ì„ ìƒê°í•´ë³´ì‹œë©´, ì»´í“¨í„° ì•ˆì— ì‚´ì•„ìˆëŠ” ìë™ì°¨, ë˜ëŠ” ìˆ˜ìˆ  ë¡œë´‡ ë‚´ë¶€ì— ë‚´ì¥ëœ ì„ë² ë””ë“œ ì œí’ˆë“¤ì„ ë– ì˜¬ë ¤ë³´ì‹­ì‹œì˜¤. ê·¸ê²ƒì´ ë°”ë¡œ ë¡œë´‡ì˜ ë‘ë‡Œì…ë‹ˆë‹¤. ë¡œë´‡ ì•ˆì˜ ë‡Œì¸ ê²ƒì´ì£ . ê·¸ë¦¬ê³  ì €í¬ê°€ ì•Œë ¤ì§„ ë˜ ë‹¤ë¥¸ ì»´í“¨í„°ëŠ” AIë¥¼ ê°œë°œí•˜ëŠ” ê²ƒìœ¼ë¡œ, NVIDIA AIë¥¼ ìœ„í•œ NVIDIA DGXì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ëŠ” ì‚¼ìœ„ì¼ì²´ì˜ ì„¸ ë²ˆì§¸ ë¶€ë¶„ì„ ë†“ì¹˜ê³  ìˆì—ˆëŠ”ë°, ê·¸ê²ƒì´ ë°”ë¡œ ë¬¼ë¦¬í•™ì— ê¸°ë°˜í•œ ê°€ìƒ ì„¸ê³„ë¥¼ ê°œë°œí•˜ëŠ” Omniverseì…ë‹ˆë‹¤.</td></tr>
<tr><td>They understand the laws of physics and they can synthetically generate virtual worlds so that the robot itself does not need to learn solely in a physical real-world environment. It is just too expensive, too costly, too dangerous. And so Omniverse, and I'm going to show you a little bit more about NVIDIA Cosmos, that was just announced at CES, is going to create that third trinity computer to allow for physical AI and the rapid capabilities of robotics in the future. We've been building NVIDIA Holoscan for many, many years now. This is our healthcare AI robot platform. In fact, Medtronic, Moon Surgical, our FDA-approved devices built on this and in market today.</td><td>ê·¸ë“¤ì€ ë¬¼ë¦¬ ë²•ì¹™ì„ ì´í•´í•˜ê³  ê°€ìƒ ì„¸ê³„ë¥¼ í•©ì„±ì ìœ¼ë¡œ ìƒì„±í•  ìˆ˜ ìˆì–´ì„œ, ë¡œë´‡ ìì²´ê°€ ë¬¼ë¦¬ì ì¸ ì‹¤ì œ í™˜ê²½ì—ì„œë§Œ í•™ìŠµí•  í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤. ê·¸ëŸ° ë°©ì‹ì€ ë„ˆë¬´ ë¹„ì‹¸ê³ , ë¹„ìš©ì´ ë§ì´ ë“¤ë©°, ìœ„í—˜í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë”°ë¼ì„œ Omniverseì™€ - CESì—ì„œ ë°©ê¸ˆ ë°œí‘œëœ NVIDIA Cosmosì— ëŒ€í•´ ì¡°ê¸ˆ ë” ë³´ì—¬ë“œë¦¬ê² ìŠµë‹ˆë‹¤ë§Œ - ì´ê²ƒì´ ë¬¼ë¦¬ì  AIì™€ ë¯¸ë˜ ë¡œë³´í‹±ìŠ¤ì˜ ì‹ ì†í•œ ì—­ëŸ‰ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ëŠ” ì„¸ ë²ˆì§¸ íŠ¸ë¦¬ë‹ˆí‹° ì»´í“¨í„°ë¥¼ ë§Œë“¤ì–´ë‚¼ ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” ìˆ˜ë…„ê°„ NVIDIA Holoscanì„ êµ¬ì¶•í•´ì™”ìŠµë‹ˆë‹¤. ì´ê²ƒì€ ì €í¬ì˜ í—¬ìŠ¤ì¼€ì–´ AI ë¡œë´‡ í”Œë«í¼ì…ë‹ˆë‹¤. ì‹¤ì œë¡œ Medtronic, Moon Surgical ë“± ì´ í”Œë«í¼ì„ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì¶•ëœ FDA ìŠ¹ì¸ ê¸°ê¸°ë“¤ì´ í˜„ì¬ ì‹œì¥ì— ì¶œì‹œë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>It really applies -- it's a universal computing platform. It's sensor-agnostic. It's the real-time processing pipeline to go from sensor in to insights out. And we've built the full stack so that now the industry can just focus on the applications and all of that computing platform has already been built. We need these devices to understand the physical world. So you've heard about language models but now we have vision language models. NVIDIA Cosmos NeMoTron, the family of models that was just announced last week has that visual understanding where you can watch a video, ask it a question, it can tell you what's going on in this video. This gives AI both temporal and spatial awareness.</td><td>ì´ê²ƒì€ ì •ë§ë¡œ ì ìš©ë©ë‹ˆë‹¤ -- ë²”ìš© ì»´í“¨íŒ… í”Œë«í¼ì…ë‹ˆë‹¤. ì„¼ì„œì— êµ¬ì• ë°›ì§€ ì•ŠìŠµë‹ˆë‹¤. ì„¼ì„œ ì…ë ¥ì—ì„œ ì¸ì‚¬ì´íŠ¸ ì¶œë ¥ê¹Œì§€ì˜ ì‹¤ì‹œê°„ ì²˜ë¦¬ íŒŒì´í”„ë¼ì¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” í’€ìŠ¤íƒì„ êµ¬ì¶•í–ˆê¸° ë•Œë¬¸ì— ì´ì œ ì—…ê³„ëŠ” ì• í”Œë¦¬ì¼€ì´ì…˜ì—ë§Œ ì§‘ì¤‘í•˜ë©´ ë˜ê³ , ëª¨ë“  ì»´í“¨íŒ… í”Œë«í¼ì€ ì´ë¯¸ êµ¬ì¶•ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ë””ë°”ì´ìŠ¤ë“¤ì´ ë¬¼ë¦¬ì  ì„¸ê³„ë¥¼ ì´í•´í•  ìˆ˜ ìˆë„ë¡ í•´ì•¼ í•©ë‹ˆë‹¤. ì–¸ì–´ ëª¨ë¸ì— ëŒ€í•´ ë“¤ì–´ë³´ì…¨ê² ì§€ë§Œ, ì´ì œ ìš°ë¦¬ì—ê²ŒëŠ” ë¹„ì „ ì–¸ì–´ ëª¨ë¸ì´ ìˆìŠµë‹ˆë‹¤. ì§€ë‚œì£¼ì— ë°œí‘œëœ NVIDIA Cosmos NeMoTron ëª¨ë¸ íŒ¨ë°€ë¦¬ëŠ” ë¹„ë””ì˜¤ë¥¼ ì‹œì²­í•˜ê³ , ì§ˆë¬¸ì„ ë°›ìœ¼ë©´ í•´ë‹¹ ë¹„ë””ì˜¤ì—ì„œ ë¬´ìŠ¨ ì¼ì´ ì¼ì–´ë‚˜ê³  ìˆëŠ”ì§€ ì•Œë ¤ì¤„ ìˆ˜ ìˆëŠ” ì‹œê°ì  ì´í•´ ëŠ¥ë ¥ì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ AIì—ê²Œ ì‹œê°„ì , ê³µê°„ì  ì¸ì‹ ëŠ¥ë ¥ì„ ëª¨ë‘ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>This has just come about in the last six or nine months. This is a necessary component but not the only necessary component. The other part of achieving physical AI is how can you create physics-aware virtual worlds. And NVIDIA Cosmos is a family of what we call world foundation models. In fact, it won number one overall at CES just last week because it's that big of a breakthrough. Imagine you have the CAD design of a robot. You can now introduce it with real physics data. Here, we're introducing it with CT scans and other type of multimodal data.</td><td>ì´ê²ƒì€ ì§€ë‚œ 6ê°œì›”ì—ì„œ 9ê°œì›” ì‚¬ì´ì— ë‚˜íƒ€ë‚œ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” í•„ìš”í•œ êµ¬ì„± ìš”ì†Œì´ì§€ë§Œ ìœ ì¼í•œ í•„ìˆ˜ êµ¬ì„± ìš”ì†ŒëŠ” ì•„ë‹™ë‹ˆë‹¤. ë¬¼ë¦¬ì  AIë¥¼ ë‹¬ì„±í•˜ëŠ” ë˜ ë‹¤ë¥¸ ë¶€ë¶„ì€ ë¬¼ë¦¬í•™ì„ ì¸ì‹í•˜ëŠ” ê°€ìƒ ì„¸ê³„ë¥¼ ì–´ë–»ê²Œ ë§Œë“¤ ìˆ˜ ìˆëŠëƒëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  NVIDIA CosmosëŠ” ìš°ë¦¬ê°€ ì„¸ê³„ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì´ë¼ê³  ë¶€ë¥´ëŠ” ì œí’ˆêµ°ì…ë‹ˆë‹¤. ì‹¤ì œë¡œ ì§€ë‚œì£¼ CESì—ì„œ ì¢…í•© 1ìœ„ë¥¼ ì°¨ì§€í–ˆëŠ”ë°, ê·¸ë§Œí¼ í° í˜ì‹ ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë¡œë´‡ì˜ CAD ì„¤ê³„ë„ê°€ ìˆë‹¤ê³  ìƒìƒí•´ë³´ì„¸ìš”. ì´ì œ ì‹¤ì œ ë¬¼ë¦¬í•™ ë°ì´í„°ì™€ í•¨ê»˜ ë„ì…í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œëŠ” CT ìŠ¤ìº”ê³¼ ê¸°íƒ€ ìœ í˜•ì˜ ë©€í‹°ëª¨ë‹¬ ë°ì´í„°ì™€ í•¨ê»˜ ë„ì…í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>These models can generate physically aware scenarios, for which we can change the camera view but it has object permanence so it knows where things are. And it can train robots in essentially infinite scenarios, which is the only way we're going to have safe and effective robots in the healthcare industry. And so we're building towards this, and it's coming along very, very quickly now. So here's a couple of industry firsts. You see amazing applications popping up out of everywhere. We're really leveraging and benefiting from this three computer trinity, Syncron, incredible.</td><td>ì´ëŸ¬í•œ ëª¨ë¸ë“¤ì€ ë¬¼ë¦¬ì ìœ¼ë¡œ ì¸ì‹ ê°€ëŠ¥í•œ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ìƒì„±í•  ìˆ˜ ìˆìœ¼ë©°, ì¹´ë©”ë¼ ì‹œì ì„ ë³€ê²½í•  ìˆ˜ ìˆì§€ë§Œ ê°ì²´ ì˜ì†ì„±ì„ ê°€ì§€ê³  ìˆì–´ ì‚¬ë¬¼ì´ ì–´ë””ì— ìˆëŠ”ì§€ ì•Œ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë³¸ì§ˆì ìœ¼ë¡œ ë¬´í•œí•œ ì‹œë‚˜ë¦¬ì˜¤ì—ì„œ ë¡œë´‡ì„ í›ˆë ¨ì‹œí‚¬ ìˆ˜ ìˆëŠ”ë°, ì´ëŠ” í—¬ìŠ¤ì¼€ì–´ ì‚°ì—…ì—ì„œ ì•ˆì „í•˜ê³  íš¨ê³¼ì ì¸ ë¡œë´‡ì„ í™•ë³´í•  ìˆ˜ ìˆëŠ” ìœ ì¼í•œ ë°©ë²•ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ë¥¼ ìœ„í•´ êµ¬ì¶•í•˜ê³  ìˆìœ¼ë©°, í˜„ì¬ ë§¤ìš° ë¹ ë¥´ê²Œ ì§„ì „ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸° ëª‡ ê°€ì§€ ì—…ê³„ ìµœì´ˆ ì‚¬ë¡€ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ëª¨ë“  ê³³ì—ì„œ ë†€ë¼ìš´ ì• í”Œë¦¬ì¼€ì´ì…˜ë“¤ì´ ë“±ì¥í•˜ê³  ìˆëŠ” ê²ƒì„ ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ ì„¸ ê°€ì§€ ì»´í“¨í„° íŠ¸ë¦¬ë‹ˆí‹°ì¸ Syncronì„ ì •ë§ë¡œ í™œìš©í•˜ê³  ê·¸ë¡œë¶€í„° í˜œíƒì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ ë†€ëìŠµë‹ˆë‹¤.</td></tr>
<tr><td>They're [stent] (ph) for brain computer interfaces so that humans who can't move can interact with the physical world. Moon Surgical's Maestro is a surgical assistant. They're training task automation where the robot will be able to move on its own. Neptune Medical and their Pathfinder for robotic endoscopy and Virtual Incision, their MIRA and their next-generation miniature robotic surgery and even being used for tele-operation. So we're just starting to see some amazing breakthrough devices come to market. So we're announcing, this is our final announcement that we are partnering with the Mayo Clinic, the number one hospital in the world for many, many specialties.</td><td>ë‡Œ-ì»´í“¨í„° ì¸í„°í˜ì´ìŠ¤ìš© [ìŠ¤í…íŠ¸](ph)ë¡œ, ì›€ì§ì¼ ìˆ˜ ì—†ëŠ” í™˜ìë“¤ì´ ë¬¼ë¦¬ì  ì„¸ê³„ì™€ ìƒí˜¸ì‘ìš©í•  ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤. Moon Surgicalì˜ MaestroëŠ” ìˆ˜ìˆ  ë³´ì¡° ì¥ì¹˜ì…ë‹ˆë‹¤. ì´ë“¤ì€ ë¡œë´‡ì´ ììœ¨ì ìœ¼ë¡œ ì›€ì§ì¼ ìˆ˜ ìˆëŠ” ì‘ì—… ìë™í™”ë¥¼ í›ˆë ¨ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. Neptune Medicalê³¼ ê·¸ë“¤ì˜ ë¡œë´‡ ë‚´ì‹œê²½ìš© Pathfinder, ê·¸ë¦¬ê³  Virtual Incisionì˜ MIRAì™€ ì°¨ì„¸ëŒ€ ì†Œí˜• ë¡œë´‡ ìˆ˜ìˆ  ì¥ë¹„ëŠ” ì›ê²© ì¡°ì‘ì—ë„ ì‚¬ìš©ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì²˜ëŸ¼ ìš°ë¦¬ëŠ” ì‹œì¥ì— ì¶œì‹œë˜ëŠ” ë†€ë¼ìš´ í˜ì‹ ì  ì˜ë£Œê¸°ê¸°ë“¤ì„ ì´ì œ ë§‰ ë³´ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ ë°œí‘œë¡œ, ìš°ë¦¬ëŠ” ì—¬ëŸ¬ ì „ë¬¸ ë¶„ì•¼ì—ì„œ ì„¸ê³„ 1ìœ„ ë³‘ì›ì¸ ë©”ì´ìš” í´ë¦¬ë‹‰ê³¼ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºëŠ”ë‹¤ê³  ë°œí‘œí•©ë‹ˆë‹¤.</td></tr>
<tr><td>And we are accelerating the next generation of AI-driven digital pathology. Mayo today announced the Mayo Digital Pathology platform. This is built on an incredibly state-of-the-art robotic digital pathology labs that has amassed a huge and unique data set of over 20 million whole-slide images that has 10 million associated patient records. We're going to -- they're going to be building this on their new NVIDIA DGX Blackwell, which has 1.4 terabytes of GPU memory, absolutely necessary for these gigantic data sets. We're going to be applying the future of Cosmos and these multimodal vision to really understand much, much more deeply about biology. So this is an incredible partnership.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” AI ê¸°ë°˜ ì°¨ì„¸ëŒ€ ë””ì§€í„¸ ë³‘ë¦¬í•™ì„ ê°€ì†í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë©”ì´ìš” í´ë¦¬ë‹‰ì€ ì˜¤ëŠ˜ ë©”ì´ìš” ë””ì§€í„¸ ë³‘ë¦¬í•™ í”Œë«í¼ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” 2ì²œë§Œ ê°œ ì´ìƒì˜ ì „ì²´ ìŠ¬ë¼ì´ë“œ ì´ë¯¸ì§€ì™€ 1ì²œë§Œ ê°œì˜ ê´€ë ¨ í™˜ì ê¸°ë¡ìœ¼ë¡œ êµ¬ì„±ëœ ê±°ëŒ€í•˜ê³  ë…íŠ¹í•œ ë°ì´í„°ì…‹ì„ ì¶•ì í•œ ìµœì²¨ë‹¨ ë¡œë´‡ ë””ì§€í„¸ ë³‘ë¦¬í•™ ì—°êµ¬ì†Œë¥¼ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì¶•ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ë“¤ì€ 1.4í…Œë¼ë°”ì´íŠ¸ì˜ GPU ë©”ëª¨ë¦¬ë¥¼ ê°–ì¶˜ ìƒˆë¡œìš´ NVIDIA DGX Blackwell ìœ„ì— ì´ë¥¼ êµ¬ì¶•í•  ì˜ˆì •ì¸ë°, ì´ëŠ” ì´ëŸ¬í•œ ê±°ëŒ€í•œ ë°ì´í„°ì…‹ì— ì ˆëŒ€ì ìœ¼ë¡œ í•„ìš”í•œ ì‚¬ì–‘ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¯¸ë˜ì˜ Cosmosì™€ ì´ëŸ¬í•œ ë©€í‹°ëª¨ë‹¬ ë¹„ì „ì„ ì ìš©í•˜ì—¬ ìƒë¬¼í•™ì— ëŒ€í•´ í›¨ì”¬ ë” ê¹Šì´ ì´í•´í•  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì •ë§ ë†€ë¼ìš´ íŒŒíŠ¸ë„ˆì‹­ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And we're tackling biology at all scale from the genomics scale all the way through the tissue scale. And by doing this, you're going to see we're going to understand biology at multiscale in the not-too-distant future. So exciting times ahead. So I will -- I'm going to wrap up now. AI agents, develop and deploy domain-specific agents. It's so important. The LLMs themselves are not domain enough in order to have the impact that we need, which is why partnering with IQVIA, their domain expertise, stretches decades of deep, deep understanding what it takes to do clinical trials. And you need to put that knowledge and understanding and deeply embed it as the AI agent.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ìœ ì „ì²´í•™ ê·œëª¨ë¶€í„° ì¡°ì§ ê·œëª¨ì— ì´ë¥´ê¸°ê¹Œì§€ ëª¨ë“  ê·œëª¨ì—ì„œ ìƒë¬¼í•™ì„ ë‹¤ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ë¨¸ì§€ì•Šì€ ë¯¸ë˜ì— ìš°ë¦¬ê°€ ë‹¤ì¤‘ ê·œëª¨ì—ì„œ ìƒë¬¼í•™ì„ ì´í•´í•˜ê²Œ ë  ê²ƒì„ ë³´ì‹œê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì •ë§ í¥ë¯¸ì§„ì§„í•œ ì‹œëŒ€ê°€ ì•ì— ìˆìŠµë‹ˆë‹¤. <br><br>ì´ì œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. AI ì—ì´ì „íŠ¸, ë„ë©”ì¸ë³„ íŠ¹í™” ì—ì´ì „íŠ¸ë¥¼ ê°œë°œí•˜ê³  ë°°í¬í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. LLM ìì²´ë§Œìœ¼ë¡œëŠ” ìš°ë¦¬ê°€ í•„ìš”ë¡œ í•˜ëŠ” ì„íŒ©íŠ¸ë¥¼ ê°€ì§€ê¸°ì— ì¶©ë¶„íˆ ë„ë©”ì¸ë³„ë¡œ íŠ¹í™”ë˜ì–´ ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ IQVIAì™€ì˜ íŒŒíŠ¸ë„ˆì‹­ì´ ì¤‘ìš”í•œ ì´ìœ ì…ë‹ˆë‹¤. ê·¸ë“¤ì˜ ë„ë©”ì¸ ì „ë¬¸ì„±ì€ ì„ìƒì‹œí—˜ ìˆ˜í–‰ì— í•„ìš”í•œ ê²ƒì´ ë¬´ì—‡ì¸ì§€ì— ëŒ€í•œ ìˆ˜ì‹­ ë…„ê°„ì˜ ê¹Šê³  ê¹Šì€ ì´í•´ë¥¼ ë°”íƒ•ìœ¼ë¡œ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ëŸ¬í•œ ì§€ì‹ê³¼ ì´í•´ë¥¼ AI ì—ì´ì „íŠ¸ì— ê¹Šì´ ë‚´ì¬í™”ì‹œì¼œì•¼ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>AI drug discovery to generate, predict, and design new molecular ideas for different types of diseases, different new disease or therapeutic platforms that are continuing to evolve. We've got to add a lot more activity and discovery in the early part to see and meet the need for medicines, the tens of thousands of disease. And we know that so much of the healthcare spend is in the form of services. We need to augment them in all ways that we can. So we see this as a several hundred billion-dollar opportunity of AI factories where we're assisting patients, doctors, nurses, drug discoverers, both digitally and physically. So don't take my word for it.</td><td>AI ì‹ ì•½ ê°œë°œì„ í†µí•´ ë‹¤ì–‘í•œ ì§ˆë³‘ ìœ í˜•ê³¼ ì§€ì†ì ìœ¼ë¡œ ì§„í™”í•˜ê³  ìˆëŠ” ìƒˆë¡œìš´ ì§ˆë³‘ ë˜ëŠ” ì¹˜ë£Œ í”Œë«í¼ì„ ìœ„í•œ ìƒˆë¡œìš´ ë¶„ì ì•„ì´ë””ì–´ë¥¼ ìƒì„±, ì˜ˆì¸¡, ì„¤ê³„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìˆ˜ë§Œ ê°€ì§€ ì§ˆë³‘ì— ëŒ€í•œ ì˜ì•½í’ˆ ìˆ˜ìš”ë¥¼ ì¶©ì¡±í•˜ê¸° ìœ„í•´ì„œëŠ” ì´ˆê¸° ë‹¨ê³„ì—ì„œ í›¨ì”¬ ë” ë§ì€ í™œë™ê³¼ ë°œê²¬ì„ ì¶”ê°€í•´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜ë£Œë¹„ ì§€ì¶œì˜ ìƒë‹¹ ë¶€ë¶„ì´ ì„œë¹„ìŠ¤ í˜•íƒœë¼ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê°€ëŠ¥í•œ ëª¨ë“  ë°©ë²•ìœ¼ë¡œ ì´ë¥¼ ë³´ê°•í•´ì•¼ í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì´ë¥¼ í™˜ì, ì˜ì‚¬, ê°„í˜¸ì‚¬, ì‹ ì•½ ê°œë°œìë“¤ì„ ë””ì§€í„¸ê³¼ ë¬¼ë¦¬ì  ë°©ì‹ ëª¨ë‘ë¡œ ì§€ì›í•˜ëŠ” AI íŒ©í† ë¦¬ì˜ ìˆ˜ì²œì–µ ë‹¬ëŸ¬ ê·œëª¨ ê¸°íšŒë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì œ ë§ë§Œ ë¯¿ì§€ ë§ˆì‹œê³ ìš”.</td></tr>
<tr><td>I'll leave you with one last video, and then Harlan and I will chat. [Video Presentation]<br><br>Thank you, everybody. Have a great JPMorgan.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ í•œ ê°€ì§€ ì˜ìƒì„ ë” ë³´ì—¬ë“œë¦¬ê³ , ê·¸ ë‹¤ìŒì— í• ë€ê³¼ ì œê°€ ëŒ€í™”ë¥¼ ë‚˜ëˆ„ê² ìŠµë‹ˆë‹¤. [ì˜ìƒ í”„ë ˆì  í…Œì´ì…˜]<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì—¬ëŸ¬ë¶„. ì¢‹ì€ JPëª¨ê±´ ì»¨í¼ëŸ°ìŠ¤ ë˜ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">â€¢ ì£¼ìš” ë°œí‘œ ë‚´ìš©:<br>- IQVIAì™€ì˜ íŒŒíŠ¸ë„ˆì‹­: ì„ìƒì‹œí—˜ ê°€ì†í™” ë° ì˜ë£Œ ë°ì´í„° í™œìš©ì„ ìœ„í•œ AI ëª¨ë¸ ê°œë°œ í˜‘ë ¥<br>- Arc Instituteì™€ ìƒë¬¼í•™ ê¸°ë°˜ ëª¨ë¸ ê°œë°œ íŒŒíŠ¸ë„ˆì‹­ ì²´ê²°<br>- Illuminaì™€ ìœ ì „ì²´ ë¶„ì„ í”Œë«í¼ í˜‘ë ¥ ë°œí‘œ<br>- Mayo Clinicê³¼ AI ê¸°ë°˜ ë””ì§€í„¸ ë³‘ë¦¬í•™ í”Œë«í¼ ê°œë°œ í˜‘ë ¥<br><br>â€¢ ì‚¬ì—… ì „ëµ ë° ì‹œì¥ ê¸°íšŒ:<br>- í—¬ìŠ¤ì¼€ì–´ AI ì‹œì¥ì„ ìˆ˜ì²œì–µ ë‹¬ëŸ¬ ê·œëª¨ë¡œ ì „ë§<br>- NVIDIA Clara í”Œë«í¼ì„ í†µí•œ ì˜ë£Œ ìƒíƒœê³„ ì§€ì›<br>- 3,500ê°œ ì´ìƒì˜ í—¬ìŠ¤ì¼€ì–´ ìŠ¤íƒ€íŠ¸ì—…ì´ NVIDIA Inception í”„ë¡œê·¸ë¨ ì°¸ì—¬<br><br>â€¢ ê¸°ìˆ  í˜ì‹ :<br>- GenMol ë“± ì‹ ê·œ AI ê¸°ë°˜ ë¶„ì ì„¤ê³„ ëª¨ë¸ ì¶œì‹œ<br>- ë¬¼ë¦¬ì  AIì™€ ë¡œë´‡ê³µí•™ ê¸°ìˆ ì„ í†µí•œ ì˜ë£Œ ì„œë¹„ìŠ¤ í˜ì‹ <br>- NVIDIA Cosmosë¥¼ í†µí•œ ê°€ìƒ í™˜ê²½ì—ì„œì˜ ë¡œë´‡ í•™ìŠµ ì§€ì›</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Question-and-Answer Session<br><br>Harlan Sur<br><br>Okay, perfect. Yeah, that was a great overview and update. Thank you, Kimberly. Oftentimes for myself, the sell-side analysts that cover NVIDIA, especially when it comes to the vertical industry segments like healthcare, your customer base, your partner base is so diverse, large pharma companies, small tech bio companies, educational institutions, research organizations. Your platform approach has meant full stack solutions for most programs, big or small, on-prem, hybrid, cloud-based, on the hardware side, DGX, compute on-prem, DGX Cloud, et cetera. And then on top of that, you've got your software stacks, right?</td><td>**ì§ˆì˜ì‘ë‹µ ì„¸ì…˜**<br><br>**í• ë€ ì„œ(Harlan Sur)**<br><br>ì¢‹ìŠµë‹ˆë‹¤, ì™„ë²½í•˜ë„¤ìš”. ì •ë§ í›Œë¥­í•œ ê°œìš”ì™€ ì—…ë°ì´íŠ¸ì˜€ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤, í‚´ë²Œë¦¬. ì €ë¥¼ í¬í•¨í•´ì„œ NVIDIAë¥¼ ë‹´ë‹¹í•˜ëŠ” ì…€ì‚¬ì´ë“œ ì• ë„ë¦¬ìŠ¤íŠ¸ë“¤ì—ê²ŒëŠ”, íŠ¹íˆ í—¬ìŠ¤ì¼€ì–´ì™€ ê°™ì€ ìˆ˜ì§ ì‚°ì—… ë¶€ë¬¸ì— ê´€í•´ì„œëŠ”, ê³ ê° ê¸°ë°˜ê³¼ íŒŒíŠ¸ë„ˆ ê¸°ë°˜ì´ ë§¤ìš° ë‹¤ì–‘í•©ë‹ˆë‹¤. ëŒ€í˜• ì œì•½íšŒì‚¬ë“¤, ì†Œê·œëª¨ í…Œí¬ ë°”ì´ì˜¤ ê¸°ì—…ë“¤, êµìœ¡ ê¸°ê´€ë“¤, ì—°êµ¬ ì¡°ì§ë“¤ê¹Œì§€ ë§ì´ì£ . ê·€í•˜ì˜ í”Œë«í¼ ì ‘ê·¼ ë°©ì‹ì€ ê·œëª¨ì˜ ëŒ€ì†Œë¥¼ ë¶ˆë¬¸í•˜ê³  ëŒ€ë¶€ë¶„ì˜ í”„ë¡œê·¸ë¨ì— ëŒ€í•´ í’€ìŠ¤íƒ ì†”ë£¨ì…˜ì„ ì˜ë¯¸í•´ì™”ìŠµë‹ˆë‹¤. ì˜¨í”„ë ˆë¯¸ìŠ¤, í•˜ì´ë¸Œë¦¬ë“œ, í´ë¼ìš°ë“œ ê¸°ë°˜ ëª¨ë‘ì—ì„œ ë§ì´ì£ . í•˜ë“œì›¨ì–´ ì¸¡ë©´ì—ì„œëŠ” DGX, ì˜¨í”„ë ˆë¯¸ìŠ¤ ì»´í“¨íŒ…, DGX í´ë¼ìš°ë“œ ë“±ì´ ìˆê³ ìš”. ê·¸ë¦¬ê³  ê·¸ ìœ„ì— ì†Œí”„íŠ¸ì›¨ì–´ ìŠ¤íƒë“¤ë„ ìˆì£ , ë§ë‚˜ìš”?</td></tr>
<tr><td>You've got base command, enterprise AI, software stacks. You've got NIMs. And then you have your different vertical industry sort of frameworks like Clara, BioNeMo, MONAI, Holoscan. I think we often wonder, how does someone like yourself managing the vertical industries, like, how do you map all of these monetization opportunities to your hardware and software programs, right? So, can you give us a sense for the mix of your business? Is it mainly subscription cloud-based type of engagements on the hardware side? Or are most of your customer engagements on-prem hardware-based systems? And what is the subscription license attach of your software and off-the-shelf frameworks?</td><td>ê¸°ë³¸ ëª…ë ¹ì–´, ì—”í„°í”„ë¼ì´ì¦ˆ AI, ì†Œí”„íŠ¸ì›¨ì–´ ìŠ¤íƒë“¤ì´ ìˆìŠµë‹ˆë‹¤. NIMë“¤ë„ ìˆê³ ìš”. ê·¸ë¦¬ê³  Clara, BioNeMo, MONAI, Holoscanê³¼ ê°™ì€ ë‹¤ì–‘í•œ ìˆ˜ì§ ì‚°ì—…ë³„ í”„ë ˆì„ì›Œí¬ë“¤ë„ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì¢…ì¢… ê¶ê¸ˆí•´í•˜ëŠ”ë°, ìˆ˜ì§ ì‚°ì—…ì„ ê´€ë¦¬í•˜ì‹œëŠ” ë¶„ê»˜ì„œëŠ” ì´ ëª¨ë“  ìˆ˜ìµí™” ê¸°íšŒë“¤ì„ í•˜ë“œì›¨ì–´ ë° ì†Œí”„íŠ¸ì›¨ì–´ í”„ë¡œê·¸ë¨ì— ì–´ë–»ê²Œ ë§¤í•‘í•˜ì‹œëŠ”ì§€ìš”? ê·¸ë˜ì„œ ê·€í•˜ì˜ ì‚¬ì—… ë¯¹ìŠ¤ì— ëŒ€í•œ ê°ì„ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ì£¼ë¡œ êµ¬ë… ê¸°ë°˜ í´ë¼ìš°ë“œ í˜•íƒœì˜ í•˜ë“œì›¨ì–´ ì¸¡ë©´ ì°¸ì—¬ì¸ê°€ìš”? ì•„ë‹ˆë©´ ëŒ€ë¶€ë¶„ì˜ ê³ ê° ì°¸ì—¬ê°€ ì˜¨í”„ë ˆë¯¸ìŠ¤ í•˜ë“œì›¨ì–´ ê¸°ë°˜ ì‹œìŠ¤í…œì¸ê°€ìš”? ê·¸ë¦¬ê³  ê·€í•˜ì˜ ì†Œí”„íŠ¸ì›¨ì–´ ë° ê¸°ì„± í”„ë ˆì„ì›Œí¬ì˜ êµ¬ë… ë¼ì´ì„ ìŠ¤ ë¶€ì°©ë¥ ì€ ì–´ë–»ê²Œ ë˜ë‚˜ìš”?</td></tr>
<tr><td>Kimberly Powell<br><br>Yeah. I think the way to think about this is everything that we build in the NVIDIA Clara platform and the ability to democratize it, we want it to -- we're driving consumption and it's going to terminate on a GPU somewhere, and we actually don't care. And so there is a huge shift in the world to cloud and we're delighted by it. And so we are working -- it used to be the days where you had to build the supercomputer. But now NVIDIA DGX Cloud is available in every public cloud, right? And so whether it'd be inferencing platforms, very high-performance computing platforms, NVIDIA Holoscan, which you, in your mind, probably think about it as running on an edge computer.</td><td>í‚´ë²Œë¦¬ íŒŒì›”<br><br>ë„¤. ì´ì— ëŒ€í•´ ìƒê°í•´ë³´ëŠ” ë°©ì‹ì€ ìš°ë¦¬ê°€ NVIDIA Clara í”Œë«í¼ì—ì„œ êµ¬ì¶•í•˜ëŠ” ëª¨ë“  ê²ƒê³¼ ì´ë¥¼ ë¯¼ì£¼í™”í•˜ëŠ” ëŠ¥ë ¥ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ê²ƒì´ ì†Œë¹„ë¥¼ ì´‰ì§„í•˜ê¸°ë¥¼ ì›í•˜ë©°, ê²°êµ­ ì–´ë”˜ê°€ì˜ GPUì—ì„œ ì¢…ë£Œë  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹¤ì œë¡œ ìš°ë¦¬ëŠ” ì–´ë””ì„œë“  ìƒê´€ì—†ìŠµë‹ˆë‹¤. ì„¸ìƒì—ëŠ” í´ë¼ìš°ë“œë¡œì˜ ê±°ëŒ€í•œ ì „í™˜ì´ ì¼ì–´ë‚˜ê³  ìˆìœ¼ë©° ìš°ë¦¬ëŠ” ì´ë¥¼ ë§¤ìš° ê¸°ë»í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì‘ì—…í•˜ê³  ìˆìŠµë‹ˆë‹¤ -- ì˜ˆì „ì—ëŠ” ìŠˆí¼ì»´í“¨í„°ë¥¼ êµ¬ì¶•í•´ì•¼ í–ˆë˜ ì‹œì ˆì´ ìˆì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ì œ NVIDIA DGX CloudëŠ” ëª¨ë“  í¼ë¸”ë¦­ í´ë¼ìš°ë“œì—ì„œ ì´ìš© ê°€ëŠ¥í•©ë‹ˆë‹¤, ë§ì£ ? ê·¸ë˜ì„œ ì¶”ë¡  í”Œë«í¼ì´ë“ , ë§¤ìš° ê³ ì„±ëŠ¥ ì»´í“¨íŒ… í”Œë«í¼ì´ë“ , NVIDIA Holoscanì´ë“  -- ì—¬ëŸ¬ë¶„ì´ ë§ˆìŒì†ìœ¼ë¡œëŠ” ì•„ë§ˆ ì—£ì§€ ì»´í“¨í„°ì—ì„œ ì‹¤í–‰ë˜ëŠ” ê²ƒìœ¼ë¡œ ìƒê°í•˜ì‹¤ í…ë°ìš”.</td></tr>
<tr><td>It runs on the cloud just the same. Every customer, no matter domain, needs to have that flexibility, especially in healthcare, right? You need to have the ability to sometimes run on-prem because that might be the company or institution's preference. It might need to run in-country because that is the sovereign AI strategy that is upon us. And so there's a huge shift into cloud. But it has a very hybrid capability because you're going to want to run the models where it makes the most sense in terms of data sovereignty, in terms of latency. But the platform is completely hybrid cloud. And so the customers get the choice. All of our software has a very simple go-to-market.</td><td>í´ë¼ìš°ë“œì—ì„œë„ ë™ì¼í•˜ê²Œ ì‘ë™í•©ë‹ˆë‹¤. ë„ë©”ì¸ì— ê´€ê³„ì—†ì´ ëª¨ë“  ê³ ê°ì€ ê·¸ëŸ¬í•œ ìœ ì—°ì„±ì„ í•„ìš”ë¡œ í•˜ë©°, íŠ¹íˆ í—¬ìŠ¤ì¼€ì–´ ë¶„ì•¼ì—ì„œëŠ” ë”ìš± ê·¸ë ‡ìŠµë‹ˆë‹¤. ë•Œë¡œëŠ” ì˜¨í”„ë ˆë¯¸ìŠ¤ì—ì„œ ì‹¤í–‰í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì´ í•„ìš”í•œë°, ì´ëŠ” í•´ë‹¹ íšŒì‚¬ë‚˜ ê¸°ê´€ì˜ ì„ í˜¸ë„ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ êµ­ê°€ ë‚´ì—ì„œ ì‹¤í–‰í•´ì•¼ í•  í•„ìš”ê°€ ìˆì„ ìˆ˜ ìˆëŠ”ë°, ì´ëŠ” ìš°ë¦¬ ì•ì— ë†“ì¸ ì£¼ê¶Œ AI ì „ëµ ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ í´ë¼ìš°ë“œë¡œì˜ ëŒ€ê·œëª¨ ì „í™˜ì´ ì¼ì–´ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŠ” ë§¤ìš° í•˜ì´ë¸Œë¦¬ë“œí•œ ì—­ëŸ‰ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ë°ì´í„° ì£¼ê¶Œ ì¸¡ë©´ì—ì„œ, ì§€ì—°ì‹œê°„ ì¸¡ë©´ì—ì„œ ê°€ì¥ í•©ë¦¬ì ì¸ ê³³ì—ì„œ ëª¨ë¸ì„ ì‹¤í–‰í•˜ê³  ì‹¶ì–´í•  ê²ƒì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ í”Œë«í¼ì€ ì™„ì „íˆ í•˜ì´ë¸Œë¦¬ë“œ í´ë¼ìš°ë“œì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê³ ê°ë“¤ì´ ì„ íƒê¶Œì„ ê°–ê²Œ ë©ë‹ˆë‹¤. ì €í¬ì˜ ëª¨ë“  ì†Œí”„íŠ¸ì›¨ì–´ëŠ” ë§¤ìš° ê°„ë‹¨í•œ ì‹œì¥ì§„ì¶œ ì „ëµì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>It's through NVIDIA AI Enterprise subscriptions. It's a very publicly known price. It's $4,500 per GPU per year, which is essentially $1 per GPU-hour. And that is the subscription of all the NVIDIA Enterprise software. And that's how we go to market. Harlan Sur<br><br>There has been a lot of discussions back at the earnings call, back at, as you mentioned, CES about the opportunities in agentic AI and multi-agent systems that address the challenges of workforce shortages, rising healthcare costs. You announced here, right, your efforts with IQVIA to accelerate research using AI agents. Like what else is NVIDIA doing in this fast-growing subsegment of digital health agents? Kimberly Powell<br><br>Yeah.</td><td>NVIDIA AI Enterprise êµ¬ë…ì„ í†µí•´ì„œì…ë‹ˆë‹¤. ì´ëŠ” ë§¤ìš° ê³µê°œì ìœ¼ë¡œ ì•Œë ¤ì§„ ê°€ê²©ìœ¼ë¡œ, GPUë‹¹ ì—°ê°„ 4,500ë‹¬ëŸ¬, ì¦‰ ë³¸ì§ˆì ìœ¼ë¡œ GPU ì‹œê°„ë‹¹ 1ë‹¬ëŸ¬ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ëª¨ë“  NVIDIA Enterprise ì†Œí”„íŠ¸ì›¨ì–´ì˜ êµ¬ë…ë£Œì…ë‹ˆë‹¤. ì´ê²ƒì´ ìš°ë¦¬ê°€ ì‹œì¥ì— ì§„ì¶œí•˜ëŠ” ë°©ì‹ì…ë‹ˆë‹¤.<br><br>**í• ë€ ì„œ(Harlan Sur)**<br><br>ì‹¤ì  ë°œí‘œì—ì„œ, ê·¸ë¦¬ê³  ë§ì”€í•˜ì‹  ëŒ€ë¡œ CESì—ì„œ ì¸ë ¥ ë¶€ì¡±, ì˜ë£Œë¹„ ìƒìŠ¹ ë¬¸ì œë¥¼ í•´ê²°í•˜ëŠ” ì—ì´ì „í‹± AIì™€ ë©€í‹° ì—ì´ì „íŠ¸ ì‹œìŠ¤í…œì˜ ê¸°íšŒì— ëŒ€í•œ ë§ì€ ë…¼ì˜ê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ AI ì—ì´ì „íŠ¸ë¥¼ í™œìš©í•œ ì—°êµ¬ ê°€ì†í™”ë¥¼ ìœ„í•œ IQVIAì™€ì˜ í˜‘ë ¥ ë…¸ë ¥ì„ ë°œí‘œí•˜ì…¨ëŠ”ë°ìš”. ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ë””ì§€í„¸ í—¬ìŠ¤ ì—ì´ì „íŠ¸ í•˜ìœ„ ë¶€ë¬¸ì—ì„œ NVIDIAê°€ ì¶”ê°€ë¡œ í•˜ê³  ìˆëŠ” ì¼ì€ ë¬´ì—‡ì¸ê°€ìš”?<br><br>**í‚´ë²Œë¦¬ íŒŒì›”(Kimberly Powell)**<br><br>ë„¤.</td></tr>
<tr><td>We're -- so NVIDIA AI Enterprise platform, as I said, one, we build the micro services. We turn these incredibly capable AI models, and we turn them into a super easy-to-use services micro service, which is an API. It's literally an API which means it can be integrated or embedded into any application out there, right? So it can just essentially become a new capability overnight by a couple of lines of code. So one is having a huge library of these models. The next thing that we're doing to democratize this is we're turning them into reference applications, these Blueprints. These are not end market applications.</td><td>ì €í¬ëŠ” -- NVIDIA AI Enterprise í”Œë«í¼ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, ì²«ì§¸ë¡œ ì €í¬ê°€ ë§ˆì´í¬ë¡œì„œë¹„ìŠ¤ë¥¼ êµ¬ì¶•í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì´ëŸ¬í•œ ë†€ë¼ìš¸ ì •ë„ë¡œ ë›°ì–´í•œ AI ëª¨ë¸ë“¤ì„ ê°€ì ¸ì™€ì„œ ë§¤ìš° ì‚¬ìš©í•˜ê¸° ì‰¬ìš´ ì„œë¹„ìŠ¤ ë§ˆì´í¬ë¡œì„œë¹„ìŠ¤, ì¦‰ APIë¡œ ì „í™˜í•©ë‹ˆë‹¤. ë§ ê·¸ëŒ€ë¡œ APIì´ê¸° ë•Œë¬¸ì— ê¸°ì¡´ì˜ ëª¨ë“  ì• í”Œë¦¬ì¼€ì´ì…˜ì— í†µí•©ë˜ê±°ë‚˜ ì„ë² ë“œë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ëª‡ ì¤„ì˜ ì½”ë“œë§Œìœ¼ë¡œ í•˜ë£¨ì•„ì¹¨ì— ìƒˆë¡œìš´ ê¸°ëŠ¥ì´ ë  ìˆ˜ ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ì´ëŸ¬í•œ ëª¨ë¸ë“¤ì˜ ë°©ëŒ€í•œ ë¼ì´ë¸ŒëŸ¬ë¦¬ë¥¼ ë³´ìœ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë¥¼ ë¯¼ì£¼í™”í•˜ê¸° ìœ„í•´ ì €í¬ê°€ í•˜ê³  ìˆëŠ” ë‹¤ìŒ ì‘ì—…ì€ ì´ë“¤ì„ ì°¸ì¡° ì• í”Œë¦¬ì¼€ì´ì…˜ì¸ ë¸”ë£¨í”„ë¦°íŠ¸ë¡œ ì „í™˜í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë“¤ì€ ìµœì¢… ì‹œì¥ ì• í”Œë¦¬ì¼€ì´ì…˜ì´ ì•„ë‹™ë‹ˆë‹¤.</td></tr>
<tr><td>They're not a SaaS you subscribe to but they're blueprints for our partners to take advantage of. And in fact, you've seen a lot of announcements more recently with NVIDIA. We're really, really getting involved with the global system integrators. Accenture and Deloitte, Quantify, Capgemini are a necessary part of the strategy so that we can take these blueprints but do that last-mile customization integration into the domain expert agents they need to become. And so that is how we really approach this. And then we have NeMo, which is the flywheel, the data flywheel. Every enterprise should be capturing all customer interactions.</td><td>ì´ë“¤ì€ êµ¬ë…í•˜ëŠ” SaaSê°€ ì•„ë‹ˆë¼ íŒŒíŠ¸ë„ˆë“¤ì´ í™œìš©í•  ìˆ˜ ìˆëŠ” ì²­ì‚¬ì§„ì…ë‹ˆë‹¤. ì‹¤ì œë¡œ ìµœê·¼ NVIDIAì™€ì˜ ë§ì€ ë°œí‘œë¥¼ ë³´ì…¨ì„ í…ë°ìš”. ì €í¬ëŠ” ê¸€ë¡œë²Œ ì‹œìŠ¤í…œ í†µí•©ì—…ì²´ë“¤ê³¼ ì •ë§ë¡œ ê¹Šì´ ê´€ì—¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. Accenture, Deloitte, Quantify, CapgeminiëŠ” ì €í¬ ì „ëµì˜ í•„ìˆ˜ì ì¸ ë¶€ë¶„ì…ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì´ëŸ¬í•œ ì²­ì‚¬ì§„ë“¤ì„ ê°€ì ¸ì™€ì„œ ê·¸ë“¤ì´ í•„ìš”ë¡œ í•˜ëŠ” ë„ë©”ì¸ ì „ë¬¸ê°€ ì—ì´ì „íŠ¸ë¡œ ë³€ëª¨í•˜ê¸° ìœ„í•œ ë¼ìŠ¤íŠ¸ë§ˆì¼ ë§ì¶¤í™” í†µí•©ì„ ìˆ˜í–‰í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì €í¬ê°€ ì ‘ê·¼í•˜ëŠ” ë°©ì‹ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ì—ê²ŒëŠ” NeMoê°€ ìˆëŠ”ë°, ì´ëŠ” í”Œë¼ì´íœ , ì¦‰ ë°ì´í„° í”Œë¼ì´íœ ì…ë‹ˆë‹¤. ëª¨ë“  ê¸°ì—…ì€ ëª¨ë“  ê³ ê° ìƒí˜¸ì‘ìš©ì„ í¬ì°©í•´ì•¼ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>They should be capturing everything about how their products are being used, and taking that as new data and intelligence to refine these agents to perform better and better and better over time. And so we've really taken that full stack approach from helping amazing companies who have unique data sets build their own proprietary foundation models, turning them into micro services, blueprint as agents and then, of course, running them on these large-scale AI factories that they can scale across the world. Harlan Sur<br><br>One of the big unveils at your developers conference last year called GTC was physical AI. You touched upon it in your presentation.</td><td>ê·¸ë“¤ì€ ìì‹ ë“¤ì˜ ì œí’ˆì´ ì–´ë–»ê²Œ ì‚¬ìš©ë˜ê³  ìˆëŠ”ì§€ì— ëŒ€í•œ ëª¨ë“  ê²ƒì„ í¬ì°©í•˜ê³ , ì´ë¥¼ ìƒˆë¡œìš´ ë°ì´í„°ì™€ ì¸í…”ë¦¬ì „ìŠ¤ë¡œ í™œìš©í•˜ì—¬ ì´ëŸ¬í•œ ì—ì´ì „íŠ¸ë“¤ì´ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ì ì  ë” ë‚˜ì€ ì„±ëŠ¥ì„ ë°œíœ˜í•˜ë„ë¡ ê°œì„ í•´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ê³ ìœ í•œ ë°ì´í„°ì…‹ì„ ë³´ìœ í•œ ë†€ë¼ìš´ ê¸°ì—…ë“¤ì´ ìì²´ì ì¸ ë…ì  íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì„ êµ¬ì¶•í•˜ê³ , ì´ë¥¼ ë§ˆì´í¬ë¡œì„œë¹„ìŠ¤ë¡œ ì „í™˜í•˜ë©°, ì—ì´ì „íŠ¸ë¡œ ì²­ì‚¬ì§„ì„ ë§Œë“¤ê³ , ë¬¼ë¡  ì „ ì„¸ê³„ì ìœ¼ë¡œ í™•ì¥í•  ìˆ˜ ìˆëŠ” ì´ëŸ¬í•œ ëŒ€ê·œëª¨ AI íŒ©í† ë¦¬ì—ì„œ ìš´ì˜í•  ìˆ˜ ìˆë„ë¡ ë•ëŠ” í’€ìŠ¤íƒ ì ‘ê·¼ ë°©ì‹ì„ ì •ë§ë¡œ ì·¨í•´ì™”ìŠµë‹ˆë‹¤.<br><br>í• ë€ ì„œ(Harlan Sur)<br><br>ì‘ë…„ GTCë¼ê³  ë¶ˆë¦¬ëŠ” ê°œë°œì ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ê³µê°œëœ í° ë°œí‘œ ì¤‘ í•˜ë‚˜ê°€ í”¼ì§€ì»¬ AIì˜€ìŠµë‹ˆë‹¤. í”„ë ˆì  í…Œì´ì…˜ì—ì„œ ì´ì— ëŒ€í•´ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”.</td></tr>
<tr><td>Jensen talked about it at the recent Consumer Electronics Show. Models that perceive, understand, interact with the physical world with one of the use cases being to train AI robots, right? Omniverse is the team's platform to simulate virtual physical roles that adhere to the laws of physics and is used to train robots. We saw the add-on capabilities with the announcement of Cosmos. Again, you talked about it, right, again, focused on physical AI. We can extend this to healthcare where robots can be used to assist in complex surgery, medical procedures. Training these robots in a virtual environment reduces risk, as you mentioned, associated with real-world trials.</td><td>ì  ìŠ¨ì´ ìµœê·¼ ì†Œë¹„ì ì „ì ì „ì‹œíšŒì—ì„œ ì´ì— ëŒ€í•´ ì–¸ê¸‰í–ˆìŠµë‹ˆë‹¤. ë¬¼ë¦¬ì  ì„¸ê³„ë¥¼ ì¸ì‹í•˜ê³ , ì´í•´í•˜ë©°, ìƒí˜¸ì‘ìš©í•˜ëŠ” ëª¨ë¸ë“¤ë¡œ, ê·¸ í™œìš© ì‚¬ë¡€ ì¤‘ í•˜ë‚˜ê°€ AI ë¡œë´‡ì„ í›ˆë ¨ì‹œí‚¤ëŠ” ê²ƒì´ì£ . ì˜´ë‹ˆë²„ìŠ¤ëŠ” ë¬¼ë¦¬ ë²•ì¹™ì„ ì¤€ìˆ˜í•˜ëŠ” ê°€ìƒ ë¬¼ë¦¬ì  ì—­í• ì„ ì‹œë®¬ë ˆì´ì…˜í•˜ëŠ” íŒ€ì˜ í”Œë«í¼ìœ¼ë¡œ, ë¡œë´‡ í›ˆë ¨ì— ì‚¬ìš©ë©ë‹ˆë‹¤. ì½”ìŠ¤ëª¨ìŠ¤ ë°œí‘œì™€ í•¨ê»˜ ì• ë“œì˜¨ ê¸°ëŠ¥ë“¤ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€í•˜ì‹  ë°”ì™€ ê°™ì´, ë¬¼ë¦¬ì  AIì— ì´ˆì ì„ ë§ì¶˜ ê²ƒì´ì£ . ì´ë¥¼ í—¬ìŠ¤ì¼€ì–´ ë¶„ì•¼ë¡œ í™•ì¥í•˜ë©´ ë¡œë´‡ì´ ë³µì¡í•œ ìˆ˜ìˆ ì´ë‚˜ ì˜ë£Œ ì‹œìˆ ì„ ë³´ì¡°í•˜ëŠ” ë° í™œìš©ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê°€ìƒ í™˜ê²½ì—ì„œ ì´ëŸ¬í•œ ë¡œë´‡ë“¤ì„ í›ˆë ¨ì‹œí‚¤ëŠ” ê²ƒì€ ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì‹¤ì œ í™˜ê²½ì—ì„œì˜ ì‹œí—˜ê³¼ ê´€ë ¨ëœ ìœ„í—˜ì„ ì¤„ì—¬ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>It seems like you guys have actually adopted Omniverse Cosmos like framework, but whereas Jensen will talk about Omniverse and Cosmos, building simulation, automotive simulation and so on, right? What's the framework for building Omniverse and Cosmos from a healthcare perspective? Kimberly Powell<br><br>Yeah. As I said, our mission in healthcare business unit is how do you take these incredible technologies but make them more domain-specific or teach the world how to use them in a domain context. And so that example I gave you where you saw the robot picking up the needle, that's doing research with a Da Vinci Research Kit, an actual research kit, right?</td><td>ë„¤, ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì—¬ëŸ¬ë¶„ì´ ì‹¤ì œë¡œ Omniverse Cosmosì™€ ê°™ì€ í”„ë ˆì„ì›Œí¬ë¥¼ ì±„íƒí•˜ì‹  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì  ìŠ¨ì´ Omniverseì™€ Cosmos, ì‹œë®¬ë ˆì´ì…˜ êµ¬ì¶•, ìë™ì°¨ ì‹œë®¬ë ˆì´ì…˜ ë“±ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ëŠ” ë°˜ë©´, í—¬ìŠ¤ì¼€ì–´ ê´€ì ì—ì„œ Omniverseì™€ Cosmosë¥¼ êµ¬ì¶•í•˜ëŠ” í”„ë ˆì„ì›Œí¬ëŠ” ë¬´ì—‡ì¸ê°€ìš”?<br><br>í‚´ë²Œë¦¬ íŒŒì›”:<br><br>ë„¤, ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ í—¬ìŠ¤ì¼€ì–´ ì‚¬ì—…ë¶€ì˜ ë¯¸ì…˜ì€ ì´ëŸ¬í•œ ë†€ë¼ìš´ ê¸°ìˆ ë“¤ì„ ì–´ë–»ê²Œ ë”ìš± ë„ë©”ì¸ë³„ë¡œ íŠ¹í™”ì‹œí‚¤ê±°ë‚˜, ë„ë©”ì¸ ë§¥ë½ì—ì„œ ì´ë¥¼ ì‚¬ìš©í•˜ëŠ” ë°©ë²•ì„ ì„¸ìƒì— ê°€ë¥´ì¹˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì œê°€ ë³´ì—¬ë“œë¦° ë¡œë´‡ì´ ë°”ëŠ˜ì„ ì§‘ëŠ” ì˜ˆì‹œëŠ” ì‹¤ì œ ì—°êµ¬ í‚¤íŠ¸ì¸ ë‹¤ë¹ˆì¹˜ ì—°êµ¬ í‚¤íŠ¸(Da Vinci Research Kit)ë¥¼ ì‚¬ìš©í•œ ì—°êµ¬ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And then using our NVIDIA AI imaging research team to understand how to take medical imaging data and turn that into physically-aware synthetic data, and then start to train this robot different policies by doing that in a simulated environment. And then we publish all of that understanding, what we've learned either in open source but also in our Holoscan reference applications. It's all on GitHub with the recipes, with the data sources, with the models that we've used. So that, again, we're trying to democratize this and show everybody how to use these amazing platforms in a domain-specific way. Harlan Sur<br><br>Well, we're just about out of time. Kimberly, thank you for your participation.</td><td>ê·¸ë¦¬ê³  ì €í¬ NVIDIA AI ì´ë¯¸ì§• ì—°êµ¬íŒ€ì„ í™œìš©í•˜ì—¬ ì˜ë£Œ ì´ë¯¸ì§• ë°ì´í„°ë¥¼ ë¬¼ë¦¬ì  ì¸ì‹ì´ ê°€ëŠ¥í•œ í•©ì„± ë°ì´í„°ë¡œ ë³€í™˜í•˜ëŠ” ë°©ë²•ì„ ì´í•´í•˜ê³ , ì‹œë®¬ë ˆì´ì…˜ í™˜ê²½ì—ì„œ ì´ë¥¼ í†µí•´ ë¡œë´‡ì—ê²Œ ë‹¤ì–‘í•œ ì •ì±…ë“¤ì„ í›ˆë ¨ì‹œí‚¤ê¸° ì‹œì‘í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ í•™ìŠµí•œ ëª¨ë“  ì´í•´ì™€ ì§€ì‹ì„ ì˜¤í”ˆì†ŒìŠ¤ë¡œ ë°œí‘œí•˜ê±°ë‚˜ Holoscan ì°¸ì¡° ì• í”Œë¦¬ì¼€ì´ì…˜ì—ì„œë„ ê³µê°œí•©ë‹ˆë‹¤. ë ˆì‹œí”¼, ë°ì´í„° ì†ŒìŠ¤, ì €í¬ê°€ ì‚¬ìš©í•œ ëª¨ë¸ë“¤ê³¼ í•¨ê»˜ ëª¨ë“  ê²ƒì´ GitHubì— ì˜¬ë¼ê°€ ìˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ ë§í•´, ì €í¬ëŠ” ì´ë¥¼ ë¯¼ì£¼í™”í•˜ê³  ì´ëŸ¬í•œ ë†€ë¼ìš´ í”Œë«í¼ë“¤ì„ ë„ë©”ì¸ë³„ë¡œ íŠ¹í™”ëœ ë°©ì‹ìœ¼ë¡œ ì‚¬ìš©í•˜ëŠ” ë°©ë²•ì„ ëª¨ë“  ì‚¬ëŒì—ê²Œ ë³´ì—¬ì£¼ë ¤ê³  ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>í• ë€ ì„œ(Harlan Sur)<br><br>ì‹œê°„ì´ ê±°ì˜ ë‹¤ ë˜ì—ˆë„¤ìš”. í‚´ë²Œë¦¬, ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We look forward to monitoring the execution of the team. Kimberly Powell<br><br>Thank you so much. Harlan Sur<br><br>Thank you very much. Kimberly Powell<br><br>Thank you.</td><td>íŒ€ì˜ ì‹¤í–‰ ê³¼ì •ì„ ì§€ì¼œë³´ê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. í‚´ë²Œë¦¬ íŒŒì›”<br><br>ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤. í• ë€ ì„œ<br><br>ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤. í‚´ë²Œë¦¬ íŒŒì›”<br><br>ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">â€¢ NVIDIA ì˜ë£Œ ì‚¬ì—…ì˜ ì£¼ìš” í¬ì¸íŠ¸ë¥¼ ë‹¤ìŒê³¼ ê°™ì´ ìš”ì•½í•©ë‹ˆë‹¤:<br><br>â€¢ ë¹„ì¦ˆë‹ˆìŠ¤ ëª¨ë¸:<br>- GPU ê¸°ë°˜ í´ë¼ìš°ë“œ ë° ì˜¨í”„ë ˜ í•˜ì´ë¸Œë¦¬ë“œ ë°©ì‹ ì œê³µ<br>- NVIDIA AI Enterprise êµ¬ë… ëª¨ë¸: GPUë‹¹ ì—°ê°„ $4,500 (ì‹œê°„ë‹¹ $1)<br>- í•˜ë“œì›¨ì–´, ì†Œí”„íŠ¸ì›¨ì–´, í”„ë ˆì„ì›Œí¬ë¥¼ í¬í•¨í•œ í’€ìŠ¤íƒ ì†”ë£¨ì…˜ ì œê³µ<br><br>â€¢ ì£¼ìš” ì „ëµì  ë°©í–¥:<br>- Accenture, Deloitte ë“± ê¸€ë¡œë²Œ SI ì—…ì²´ë“¤ê³¼ì˜ íŒŒíŠ¸ë„ˆì‹­ ê°•í™”<br>- AI ì—ì´ì „íŠ¸ ê°œë°œì„ ìœ„í•œ ë¸”ë£¨í”„ë¦°íŠ¸ ì œê³µ<br>- ì˜ë£Œ ë¶„ì•¼ íŠ¹í™” ë¬¼ë¦¬ì  AI ë° ë¡œë´‡ ì‹œë®¬ë ˆì´ì…˜ ê¸°ìˆ  ê°œë°œ<br><br>â€¢ ë¦¬ìŠ¤í¬/ê¸°íšŒ ìš”ì¸:<br>- ë°ì´í„° ì£¼ê¶Œ ë° êµ­ê°€ë³„ ê·œì œì— ë”°ë¥¸ í´ë¼ìš°ë“œ/ì˜¨í”„ë ˜ ìœ ì—°ì„± í•„ìš”<br>- ì˜ë£Œ ì¸ë ¥ ë¶€ì¡± ë° ë¹„ìš© ìƒìŠ¹ ë¬¸ì œ í•´ê²°ì„ ìœ„í•œ AI ì†”ë£¨ì…˜ ìˆ˜ìš” ì¦ê°€</p>
    <hr style="margin:50px 0;">
    
</body></html>